

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 279/18, 271/22, C07D 207/16, C07C 237/34, 233/51, 275/24, A61K 31/165, 31/16, 31/27, 31/155, 31/17	A1	(11) International Publication Number: WO 95/32945 (43) International Publication Date: 7 December 1995 (07.12.95)
(21) International Application Number: PCT/US95/06926 (22) International Filing Date: 31 May 1995 (31.05.95) (30) Priority Data: 08/252,099 1 June 1994 (01.06.94) US (71) Applicant: ARRIS PHARMACEUTICAL CORPORATION [US/US]; Suite 3, 385 Oyster Point Boulevard, South San Francisco, CA 94080 (US). (72) Inventors: LUM, Robert, T.; 781 Barron Avenue, Palo Alto, CA 94306 (US). GSCHWEND, Heinz, W.; 2710 All View Way, Belmont, CA 94002 (US). BAUER, Barr, E.; 731 Widgeon Street, Foster City, CA 94404 (US). KUO, Elaine; One St. Francis Place #6102, San Francisco, CA 94107 (US). RICE, Ken; 206 Redwood Avenue, Redwood City, CA 94061 (US). (74) Agents: DOW, Karen, B. et al.; Townsend and Townsend Khourie and Crew, 20th floor, One Market Plaza, Steuart Street Tower, San Francisco, CA 94105 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOSITIONS AND METHODS FOR TREATING MAST-CELL MEDIATED CONDITIONS		
(57) Abstract The present invention describes compounds, methods and compositions effective to treat mast-cell mediated inflammatory conditions, such as conjunctivitis, asthma and allergic rhinitis. The compounds of the invention comprise novel mono- and di-aminomethylbenzyl, aminobenzyl, guanidylbenzyl and benzyl tryptase inhibitors. The compositions for treating mast-cell mediated inflammatory conditions include oral, inhalant and topical preparations as well as devices comprising such preparations.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

COMPOSITIONS AND METHODS FOR TREATING
MAST-CELL MEDIATED CONDITIONS

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part application of co-pending U.S. Application Number 08/252,099, filed June 1, 1994.

BACKGROUND OF THE INVENTION

5

1. Field of the Invention

10

15

20

This invention relates to compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders. The invention includes compositions and methods effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis. The compositions and methods of the present invention are especially useful for preventing or treating the late phase bronchoconstriction and airway hyperresponsiveness associated with chronic asthma. In addition, the compositions and methods of the present invention have utility in treating other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, as well as various dermatological conditions.

2. Description of the Background Art

25

30

Asthma is a complex disease involving multiple biochemical mediators for both its acute and chronic manifestations. Increasingly, asthma is recognized as an inflammatory disorder (see, e.g., Hood, et al., IMMUNOLOGY 2nd ed., (Benjamin-Cummings 1984). Asthma frequently is characterized by progressive development of hyperresponsiveness of the trachea and bronchi to both immunospecific allergens and generalized chemical or physical stimuli. The hyper-responsiveness of asthmatic bronchiolar tissue is believed to

result from chronic inflammation reactions, which irritate and damage the epithelium lining the airway wall and promote pathological thickening of the underlying tissue. Bronchial biopsy studies have indicated that even patients with mild asthma have features of inflammation in the airway wall.

One initiator of the inflammatory sequence is an allergic response to inhaled allergens. Leukocytes carrying IgE receptors, notably mast cells and basophils, but also including monocytes, macrophages, and eosinophils, are present in the epithelium and underlying smooth muscle tissues of bronchi, where they are activated initially by binding of specific inhaled antigens to the IgE receptors. Activated mast cells release a number of preformed or primary chemical mediators of the inflammatory response and enzymes. Furthermore, numerous secondary mediators of inflammation are generated *in situ* by enzymatic reactions of activated mast cells, including superoxide and lipid derived mediators. In addition, several large molecules are released by degranulation of mast cells: proteoglycans, peroxidase, arylsulfatase B, and notably the proteases tryptase and chymotryptic proteinase (chymase). See DRUG THERAPY OF ASTHMA, pp. 1054-54.

This chemical release from mast cells probably accounts for the early bronchiolar constrictor response that occurs in susceptible individuals after exposure to airborne allergens. The early asthmatic reaction is maximal at around fifteen minutes after allergen exposure; recovery occurs over the ensuing one to two hours. In 25-35% of individuals, the early asthmatic reaction is followed by a further decline in respiratory function which begins within a few hours and is maximal between six and twelve hours post-exposure. This late asthmatic reaction is accompanied by a marked increase in the number of inflammatory cells infiltrating bronchiolar smooth muscle and epithelial tissues, and spilling into the airways. These cells include eosinophils, neutrophils, and lymphocytes, all of which are attracted to the site by release of mast cell derived chemotactic agents. The infiltrating cells themselves become activated during the late reaction phase. The late asthmatic response is believed to be a secondary inflammatory

reaction mediated in part by the secretory activity of macrophages.

Tryptase is the major secretory protease of human mast cells and is proposed to be involved in neuropeptide processing and tissue inflammation. Mature human tryptase is a glycosylated, heparin-associated tetramer of heterogenous, catalytically active subunits. See, e.g., Vanderslice et al. *Proc. Natl. Acad. Sci. USA* 87:3811-3815 (1990); Miller et al. *J. Clin. Invest.* 86:864-870 (1990); Miller et al. *J. Clin. Invest.* 84:1188-1195 (1989); and Vanderslice et al. *Biochemistry* 28:4148-4155 (1989).

Tryptase is stored in mast cell secretory granules. After mast cell activation, human tryptase can be measured readily in a variety of biologic fluids. For example, after anaphylaxis, tryptase appears in the bloodstream, where it remains detectable for several hours. See Schwartz et al., *N. Engl. J. Med.* 316:1622-1626 (1987). Its appearance has been detected in samples of nasal and lung lavage fluid from atopic subjects challenged with specific antigen. See Castells and Schwartz, *J. Allerg. Clin. Immunol.* 82:348-355 (1988) and Wenzel, et al., *Am. Rev. Resp. Dis.* 141:563-568 (1988). Tryptase levels in lung lavage fluid obtained from atopic asthmatics increase after endobronchial allergen challenge. Some smokers of cigarettes have striking elevations of bronchoalveolar lavage fluid tryptase levels compared to nonsmoker control groups, a finding that provides some support for the hypothesis that release of proteinases from activated mast cells could contribute to lung destruction in smoker's emphysema. See Kalenderian, et al., *Chest* 94:119-123 (1988). In addition, tryptase has been shown to be a potent mitogen for fibroblasts, suggesting its involvement in pulmonary fibrosis and interstitial lung diseases. See Ruoss et al., *J. Clin. Invest.* 88:493-499 (1991).

Tryptase has been implicated in a variety of biological processes, including degradation of vasodilating and bronchorelaxing neuropeptides (see Caughey, et al., *J. Pharmacol. Exp. Ther.* 244:133-137 (1988); Franconi, et al., *J. Pharmacol. Exp. Ther.* 248:947-951 (1988); and Tam, et al., *Am.*


J. Respir. Cell Mol. Biol. 3:27-32 (1990)) and modulation of bronchial responsiveness to histamine (see Sekizawa, et al., *J. Clin. Invest.* 83:175-179 (1989)). These studies suggest that tryptase possibly increases bronchoconstriction in asthma by destroying bronchodilating peptides.

Additionally, tryptase has been shown to cleave fibrinogen α -chains, as well as high molecular weight kininogen with a possible release of kinins and thus, may play a role with heparin as a local anticoagulant. The ability of tryptase to activate prostromelysin (pro-MMP-3) and procollagenase (pro-MMP-1) via MMP-3 suggests that tryptase also may be involved in tissue inflammation and remodeling. This finding also intimates that tryptase may play a role in joint destruction in rheumatoid arthritis. In addition, tryptase has been shown to cleave calcitonin gene-related peptide. As this peptide is implicated in neurogenic inflammation, tryptase could be a factor in the regulation of flare reaction in cutaneous neurogenic inflammation. See Caughey, *Am. J. Respir. Cell Mol. Biol.* 4:387-394 (1991).


Mast cell mediated inflammatory conditions are a growing public health concern. In particular, asthma has become a common chronic disease in industrialized countries. Therefore, it would be desirable to provide improved compositions and methods for providing effective treatment for these diseases.

SUMMARY OF THE INVENTION

The present invention provides compounds effective to inhibit tryptase activity comprising the structure:



and its pharmaceutically acceptable salts. Y may be arylene or substituted arylene, and Z and Z' are independently



where T is $-\text{CH}_2\text{NH}_2$ or $-\text{NHC}(\text{NH})\text{NH}_2$; and p is an integer between 4 and 10 inclusive. X^1 , X'^1 , X^5 and X'^5 are methylene or substituted methylene, and n_1 , n'_1 , n_5 and n'_5 independently are 0 or 1. X^2 , X'^2 , X^4 and X'^4 are selected independently from the group consisting of $-\text{NRC}(\text{O})-$, $-\text{NRC}(\text{O})\text{NR}'-$, $-\text{NRC}(\text{O})\text{O}-$, $-\text{C}(\text{O})\text{NR}-$ and $-\text{OC}(\text{O})\text{NR}-$, wherein R and R' are selected independently from the group consisting of hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, aralkyl and substituted aralkyl; and X^3 and X'^3 are selected independently from the group consisting of cycloalkylene, cycloheteroalkylene, substituted cycloalkylene, and substituted cycloheteroalkylene, lower alkylene and substituted lower alkylene.

Preferred compounds are those wherein Y is phenyl or substituted phenyl, and Z and Z' are 4-aminomethylphenyl, 4-aminomethylcyclohexyl, or 4-guanidylphenyl. More preferred are compounds wherein Y, Z and Z' are as just described and X^1 , X'^1 , X^5 and X'^5 are methylene, X^2 , X'^2 , X^4 and X'^4 are $-\text{NHC}(\text{O})-$, $-\text{C}(\text{O})\text{NH}-$, $-\text{NHC}(\text{O})\text{O}-$, and $-\text{OC}(\text{O})\text{NH}-$, respectively, and X^3 and X'^3 are ethylene or propylene.

Examples of especially preferred compounds include: bis(p-xylylenediamineglycine)-1,4-benzenedimethanol dicarbamate; bis(p-xylylenediaminesarcosine)-1,4-benzenedimethanol dicarbamate; N,N'-bis(4-aminomethylbenzamido-propylene)-1,4-benzenedimethanol dicarbamate; N,N'-bis(4-aminomethylbenzamidoethylene)-1,4-benzenedimethanol dicarbamate, and N,N'-bis(4-guanidylbenzylaminecarbonylmethylene)-1,4-benzenedimethanol dicarbamate.

The present invention also provides for pharmaceutical compositions of the compounds of the invention.

These pharmaceutical compositions can be in a variety of forms including oral dosage forms, inhalable forms, as well as injectable and infusible solutions. When used for the treatment of immunomediated inflammatory skin conditions, the compounds of the present invention are used in combination with a non-toxic, pharmaceutically acceptable topical carrier. The compounds of the present invention can be used in combination with antiinflammatories or other asthma therapies, such as β -adrenergic agonists, anti-inflammatory corticosteroids, anticholinergics, bronchodilators such as methyl xanthenes and the like.

The compounds described herein are useful for the prevention and treatment of immunomediated inflammatory disorders, and particularly those associated with the respiratory tract, including asthma, and particularly the hyperresponsiveness phase associated with chronic asthma, and allergic rhinitis. Thus, the present invention also provides a method for treating immunomediated inflammatory disorders wherein a patient having an immunomediated inflammatory disorder that is susceptible to treatment with a tryptase inhibitor receives, or is administered, a therapeutically effective dose or amount of a compound of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphical representation of the Specific Lung Resistance (SRL) as a function of time (in hours) of antigen-challenged sheep treated with N,N'-bis(4-guanidylbenzylaminocarbonylmethylene)-1,4-benzene-dimethanol dicarbamate, Compound 2 of Table II, and sheep treated with a control.

Figure 2 is a graphical representation of the Specific Lung Resistance (SRL) as a function of time (in hours) of antigen-challenged sheep treated with N,N'-bis((N-(4-amino-methylbenzyl)succinamido))-p-xylylenediamine, Compound 8 of Table II, and sheep treated with a control.

Figure 3 is a bar chart showing the airway hyperresponsiveness (measured as PC400) antigen-challenged

sheep treated with N,N'-bis(4-guanidylbenzylamine-carbonylmethylene)-1,4-benzenedimethanol dicarbamate, Compound 2 of Table II, of the invention versus sheep treated with a control.

5 Figure 4 is a bar chart showing the airway hyperresponsiveness (measured as PC400) antigen-challenged sheep treated with N,N'-bis((N-(4-aminomethylbenzyl)succinamido))-p-xylylenediamine, Compound 8 of Table II, versus sheep treated with a control.

10 Figure 5 is a graphical representation of the Specific Lung Resistance (SRL) as a function of time (in hours) of antigen-challenged sheep treated with N,N'-bis(4-guanidylbenzylaminecarbonylmethylene)-1,4-benzenedimethanol dicarbamate, Compound 2 of Table II, of the invention in an orally delivered composition and sheep treated with a control.

DESCRIPTION OF THE PREFERRED EMBODIMENT

I. Definitions

20 The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

25 "Immunomediated inflammatory disorder" includes generally those diseases associated with mast cell mediator release and susceptible to treatment with a tryptase inhibitor. Examples of such disorders include diseases of immediate type hypersensitivity such as asthma, allergic rhinitis, urticaria and angioedema, and eczematous dermatitis (atopic dermatitis), and anaphylaxis, as well as hyperproliferative skin disease, peptic ulcers, inflammatory bowel disorder, ocular and vernal conjunctivitis, rheumatoid arthritis, inflammatory skin conditions, and the like.

30 "Hyperresponsiveness" refers to late phase bronchoconstriction and airway hyperreactivity associated with chronic asthma. Hyperresponsiveness of asthmatic bronchiolar tissue is believed to result from chronic inflammation reactions, which irritate and damage the epithelium lining the airway wall and promote pathological thickening of the underlying tissue.

"Halogen" refers to fluorine, bromine, chlorine, and iodine atoms.

"Hydroxyl" refers to the group -OH.

"Thiol" or "mercapto" refers to the group -SH.

5 The term "alkoxyl" denotes the group -OR, where R is lower alkyl, substituted lower alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl as defined below.

10 The term "alkylthio" denotes the group -SR, where R is lower alkyl, substituted lower alkyl, aryl, substituted aryl aralkyl or substituted aralkyl as defined below.

 The term "acyl" denotes groups -C(O)R, where R is alkyl or substituted alkyl, aryl, or substituted aryl as defined below.

15 The term "aryloxyl" denotes groups -OAr, where Ar is an aryl or substituted aryl group as defined below.

 The term "amino" denotes the group NRR', where R and R' may independently be hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl as defined below or acyl.

20 The term "amido" denotes the group -C(O)NRR', where R and R' may independently be hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl as defined below or acyl.

25 "Lower alkyl" refers to a cyclic, branched or straight chain, alkyl group of one to eight carbon atoms. This term is further exemplified by such groups as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, i-butyl (or 2-methylpropyl), cyclopropylmethyl, i-amyl, n-amyl, and hexyl. "Substituted lower alkyl" refers to lower alkyl as just described including one or more functional groups such as lower alkyl, aryl, aralkyl, acyl, halogen, hydroxyl, amino, mercapto and the like. These groups may be attached to any carbon atom of the lower alkyl moiety.

30

 "Aryl" or "Ar" refers to an aromatic carbocyclic group having at least one aromatic ring (e.g., phenyl or biphenyl) or multiple condensed rings in which at least one ring is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl). "Substituted aryl" refers to aryl optionally substituted with one or more functional groups,

35

.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, hydroxyl and the like.

"Arylene" refers to a doubly substituted aromatic carbocyclic group having at least one aromatic ring (e.g., phenyl or biphenyl) or multiple condensed rings in which at least one ring is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl). "Substituted arylene" refers to arylene optionally substituted with one or more functional groups, e.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, hydroxyl and the like.

"Heterocycle" refers to a saturated, unsaturated, or aromatic carbocyclic group having a single ring (e.g., morpholino, pyridyl or furyl) or multiple condensed rings (e.g., naphthyridinyl, quinoxalyl, quinolinyl, indolizinyl or benzo[b]thienyl) and having at least one hetero atom, such as N, O or S, within the ring, which can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, and hydroxy. The term "heteroaryl" or "HetAr" refers to a heterocycle in which at least one heterocyclic ring is aromatic.

"Aralkyl" refers to the group -R-Ar where Ar is an aryl group and R is straight-chain or branched-chain aliphatic group. Aralkyl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, and hydroxy.

"Heteroarylalkyl" refers to the group -R-HetAr where HetAr is an heteroaryl group and R is straight-chain or branched-chain aliphatic group. Heteroarylalkyl groups can optionally be unsubstituted or substituted with, e.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, and hydroxy.

"Aylene" refers herein to a divalent lower alkyl substituent as defined above, such as methylene (-CH₂-), ethylene (-CH₂CH₂-) or propylene (-CH₂CH₂CH₂-).

"Cycloalkylene" refers to a divalent cyclic or polycyclic alkyl group containing 3 to 12 carbon atoms.

"Substituted cycloalkylene" refers to a cycloalkylene group comprising one or more substituents, e.g., halogen, lower alkyl, lower alkoxyl, lower alkylthio, trifluoromethyl, lower acyloxy, and hydroxyl.

5 "Cycloheteroalkylene" refers to a cycloalkylene group wherein one or more of the ring carbon atoms is replaced with a heteroatom (e.g., N, O, S or P). "Substituted cycloheteroalkylene" refers to a cycloheteroalkylene group as herein defined which contains one or more substituents, such as
10 halogen, lower alkyl, lower alkoxyl, lower alkylthio, trifluoromethyl, lower acyloxy, and hydroxyl.

"Pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the parent compound and which are not biologically or
15 otherwise undesirable.

"Pharmaceutically or therapeutically acceptable carrier" refers to a carrier medium which does not interfere with the effectiveness of the biological activity of the active ingredients and which is not toxic to the host or patient.


20 "Stereoisomer" refers to a chemical compound having the same molecular weight, chemical composition, and constitution as another, but with the atoms grouped differently. That is, certain identical chemical moieties are at different orientations in space and, therefore, when pure,
25 has the ability to rotate the plane of polarized light. However, some pure stereoisomers may have an optical rotation that is so slight that it is undetectable with present instrumentation. The compounds of the present invention may have one or more asymmetrical carbon atoms and therefore
30 include various stereoisomers. All stereoisomers are included within the scope of the invention.

"Treatment" or "treating" refers to any administration of a tryptase inhibitor *in vitro* or *in vivo* and includes:


- 35 (i) inhibiting the symptoms of the disease; and/or
(ii) lessening or inhibiting the long term effects of the disease.

II. Tryptase Inhibitors

The present invention includes compounds having the general structure:



5 and their pharmaceutically acceptable salts. Y is arylene or substituted arylene. Z and Z' independently are




where T is $-\text{CH}_2\text{NH}_2$ or $-\text{NHC}(\text{NH})\text{NH}_2$; and p is an integer between 0 and 10 inclusive.

10 X^1 , X'^1 , X^5 and X'^5 are methylene or substituted methylene, and n_1 , n'_1 , n_5 and n'_5 independently are 0 or 1. X^2 , X'^2 , X^4 and X'^4 are selected independently from the group consisting of $-\text{NRC}(\text{O})-$, $-\text{C}(\text{O})\text{NR}-$, $-\text{NRC}(\text{O})\text{NR}'-$, $-\text{NRC}(\text{O})\text{O}-$ and $-\text{OC}(\text{O})\text{NR}-$, wherein R and R' are selected independently from the
15 group consisting of hydrogen, lower alkyl, aryl, substituted lower alkyl, substituted aryl, aralkyl and substituted aralkyl. X^3 and X'^3 are selected independently from the group consisting of cycloalkylene, cycloheteroalkylene, substituted cycloalkylene, and substituted cycloheteroalkylene, lower
20 alkylene and substituted lower alkylene.

In preferred embodiments, Y is arylene carrying one or more substituents. Typical substituents include halogen, alkoxyl, hydroxyl, alkylthio, carboxyl, mercapto, amido, alkyl, aryl, heteroaryl, aryloxy, cyano, alkylcarbonyl, arylcarbonyl,
25 alkylimino, arylimino, alkyliminoxyl, aryliminoxyl, nitro, sulfate, sulfonate, phosphate and phosphonate. More preferably, Y is phenylene or phenylene substituted as just described.

Z and Z' independently are



where T is aminomethyl or guanidyl and p is an integer from 0 to 10 inclusive. Thus, Z and Z' independently may include a phenyl, cyclohexadienyl, cyclohexenyl or cyclohexyl ring structure which includes either an aminomethyl or guanidyl group. Preferably, the substituent T is attached to the ring at a carbon meta or para to the carbon at which the ring is attached to the remainder of the molecule. If the ring is phenyl, it may carry one or more substituents such as, but not limited to, halogen, alkoxyl, hydroxyl, alkyl, aryl, heteroaryl, aryloxyl and cyano. Preferred embodiments are those wherein p is 4 or 10, i.e., wherein the ring is phenyl or cyclohexyl. More preferred are those embodiments wherein p is 4 and T is aminomethyl. Still more preferred are those embodiments wherein p is 4 and T is aminomethyl or -NHC(NH)NH₂ and attached to the ring at the carbon para to the carbon atom at which the ring is attached to the molecule.

The compounds of the present invention may include groups X¹ and/or X'¹, depending on whether the value of n₁ and/or n'₁ is 0 or 1. When n₁ (or n'₁) is 0, the group X¹ (or X'¹) is not a constituent of the molecule, and the Z (or Z') moiety is attached directly to X² (or X'²). When n₁ or n'₁ is 1, Z (or Z') is attached to X¹ (or X'¹). Similarly, when n₅ (or n'₅) is 0, the group Y is attached directly to X⁴ (or X'⁴).

X¹, X'¹, X⁵ and X'⁵ may independently be methylene or substituted methylene. Typical substituents include halogen, alkoxyl, hydroxyl, alkylthio, mercapto, carboxyl, amido, alkyl, aryl, heteroaryl, aryloxyl, cyano, alkylcarbonyl, arylcarbonyl, alkylimino, arylimino, alkyliminoxyl, aryliminoxyl, nitro,

sulfate, sulfonate, phosphate and phosphonate. Preferably, X^1 , X'^1 , X^5 and X'^5 are each methylene.


X^2 , X'^2 , X^4 and X'^4 are selected independently from the group consisting of $-NRC(O)-$, $-C(O)NR-$, $-NRC(O)NR'-$, $-NRC(O)O-$ and $-OC(O)NR-$, wherein R and R' are selected independently from the group consisting of hydrogen, lower alkyl, aryl, substituted lower alkyl, substituted aryl, aralkyl, and substituted aralkyl. It will be appreciated that the groups $-NRC(O)-$ and $-NRC(O)O-$ will define different embodiments depending on their orientation in the molecule. Thus, it will be understood herein that $-NRC(O)-$ refers to an embodiment in which the group to the left of $-NRC(O)-$ (i.e., Z, X^1 , X^3 , X'^3 , X'^5 or Y) is attached to the nitrogen and the group to the right of $-NRC(O)-$ (i.e., X^3 , X^5 , Y, X'^3 , X'^1 or Z') is attached to the carbonyl carbon. Similarly, $-C(O)NR-$ refers to an embodiment which has the group to the left of $-C(O)NR-$ (i.e., Z, X^1 , X^3 , X'^3 , X'^5 or Y) attached to the carbonyl carbon and the group to the right of $-C(O)NR-$ (i.e., X^3 , X^5 , Y, X'^3 , X'^1 or Z') attached to the nitrogen. The same is to be understood for the case wherein X^2 (or X'^2 , X^4 or X'^4) is $-NRC(O)O-$ or $NRC(O)NR'-$ (where R and R' have different chemical identities).

X^3 and X'^3 are selected independently from the group consisting of cycloalkylene, cycloheteroalkylene, substituted cycloalkylene, lower alkylene and substituted lower alkylene. Typical substituents include halogen, alkoxyl, hydroxyl, alkylthio, mercapto, carboxyl, amido, alkyl, aryl, heteroaryl, aryloxy, cyano, alkylcarbonyl, arylcarbonyl, alkylimino, arylimino, alkyliminoxyl, aryliminoxyl, nitro, sulfate, sulfonate, phosphate and phosphonate. Preferred embodiments are those wherein X^3 and X'^3 are selected independently from the group consisting of methylene, ethylene and propylene. However, it is also preferred that X^3 and X'^3 are not methylene when X^2 and X^4 are both $-NRC(O)-$, and X'^4 and X'^2 are both $-C(O)NR-$, respectively.

Preferred combinations of X^1 - X^5 and X'^1 - X'^5 are shown in Table I below (\emptyset signifies no group present).

Table I


$x^1 (x'^1)$	$x^2 (x'^2)$	$x^3 (x'^3)$	$x^4 (x'^4)$	$x^5 (x'^5)$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-\text{CH}_2-$	$-\text{HNC}(\text{O})\text{O}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_2-$	$-\text{C}(\text{O})\text{NH}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_2-$	$-\text{C}(\text{O})\text{NH}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_2-$	$-\text{C}(\text{O})\text{NH}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-\text{CH}_2-$	$-\text{C}(\text{O})\text{NR}-$	$-\text{CH}_2-$
\emptyset	$-\text{C}(\text{O})\text{NH}-$	$-(\text{CH}_2)_3-$	$-\text{RNC}(\text{O})\text{O}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_3-$	$-\text{C}(\text{O})\text{NH}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_3-$	$-\text{HNC}(\text{O})-$	\emptyset
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-\text{CH}_2-$	$-\text{HNC}(\text{O})\text{O}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_3-$	$-\text{C}(\text{O})\text{NR}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-\text{CH}_2-$	$-\text{HNC}(\text{O})\text{O}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_2-$	$-\text{C}(\text{O})\text{NH}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_3-$	$-\text{C}(\text{O})\text{NH}-$	$-\text{CH}_2-$
\emptyset	$-\text{C}(\text{O})\text{NH}-$	$-(\text{CH}_2)_3-$	$-\text{C}(\text{O})\text{NH}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_2-$	$-\text{HNC}(\text{O})\text{O}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_2-$	$-\text{C}(\text{O})\text{NH}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_3-$	$-\text{C}(\text{O})\text{NH}-$	$-\text{CH}_2-$
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_3-$	$-\text{RNC}(\text{O})-$	\emptyset
$-\text{CH}_2-$	$-\text{HNC}(\text{O})-$	$-(\text{CH}_2)_2-$	$-\text{C}(\text{O})\text{NR}-$	$-\text{CH}_2-$

	-CH ₂ -	-HNC(O)-	-(CH ₂) ₂ -	-C(O)NH-	-CH ₂ -
	-CH ₂ -	-HNC(O)-	-(CH ₂) ₂ -	-C(O)NH-	-CH ₂ -
	-CH ₂ -	-HNC(O)-	-(CH ₂) ₃ -	-C(O)NR-	-CH ₂ -
	-CH ₂ -	-HNC(O)-	-CH ₂ -	-C(O)NH-	-CH ₂ -
5	-CH ₂ -	-HNC(O)-	-CH ₂ -	-C(O)NH-	-CH ₂ -
	∅	-C(O)NH-	-(CH ₂) ₄ -	-HNC(O)-	∅
	∅	-C(O)NH-	-(CH ₂) ₂ -	-HNC(O)O-	-CH ₂ -
	-CH ₂ -	-HNC(O)-		-C(O)NH-	-CH ₂ -
	-CH ₂ -	-HNC(O)-	-CH ₂ -	-C(O)NH-	-CH ₂ -
10	-CH ₂ -	-HNC(O)-	-(CH ₂) ₂ -	-C(O)NH-	-CH(CO ₂ H)-

Generally, the compounds of the invention are synthesized using standard techniques and reagents. It will be noted that the linkages between the various groups, Z, Z', X¹-X⁵ and X'¹-X'⁵, comprise carbon linked to the nitrogen of an amide or carbamate, the oxygen of a carbamate or the carbon of a carbonyl. Those of skill in the art will recognize that methods and reagents for forming these bond are well known and readily available. See, e.g., March, ADVANCED ORGANIC CHEMISTRY, 4th Ed. (Wiley 1992), Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, et al. and Furniss, VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY 5th ed. (Longman 1989), each of which is incorporated herein by reference. It will also be appreciated that any functional groups present may require protection and deprotection at different points in the synthesis of the compounds of the invention. Those of skill in the art will also recognize that such techniques are well known

(see, e.g., Green and Wuts, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY (Wiley 1992), also incorporated herein by reference).

5 The various groups Z, Z', X¹-X⁵ and X'¹-X'⁵ which comprise the target molecule to be synthesized may be added individually, or as larger chemical subunits which together form the desired molecule. Thus, for example, where it is desired that X⁵ and X'⁵ are -CH₂-, Y is phenylene, and X⁴ and X'⁴ are -NHC(O)O- or -HNC(O)NH-, p-diaminoxylylene (H₂NCH₂-C₆H₄-CH₂NH₂) may be used to supply the Y, X⁵ and X'⁵ groups as well as a nitrogen of the X⁴ and X'⁴ groups. 10 Similarly, where Y and X⁵ and X'⁵ are defined as above, and X⁴ and X'⁴ are -OC(O)NH-, dihydroxyxylylene may be used. Reaction of this unit with phosgene, followed by reaction with a group such as N-BocZ-X¹-X²-X³-OH or N-BocZ-X¹-X²-X³-NH₂ under standard 15 conditions, forms the corresponding symmetrical molecules as illustrated below. Those of skill in the art will appreciate that other equivalent synthetic pathways are possible.








Similar methodologies to those just described are employed for cases where Y is arylene other than phenylene or substituted arylene, e.g., Y is 1,4-naphthyl, 2-bromophenyl, or 3-methyl-2,6-naphthyl. For those cases where X⁵ and X'⁵ are not included, i.e., n₅ and n'₅ are both 0, p-dihydroxybenzene or p-diaminobenzene may be used instead of dihydroxy- or

diaminoxilylene. The synthesis may be performed by analogy to the steps outlined above.

The synthesis of asymmetric compounds may be accomplished using the techniques described in conjunction with appropriate starting materials and/or appropriate selective protection and deprotection strategies. For example, where either n_5 or n'_5 is 0, but the remainder of the molecule is symmetric, the strategy just discussed may be employed using 4-hydroxybenzyl alcohol or 4-aminobenzylamine.

Alternatively, compounds having functional groups with different reactivities may be chosen. Following reaction at a desired first functional group, a second functional group may be converted to a more reactive form. For example, as shown below, 4-nitroaniline or 4-nitrobenzylamine may be used to form an amide selectively at one side of Y using standard synthetic techniques as just described, as the nitro group is unreactive towards acylation. (R^1 and R^2 represent $Z-X^1-X^2-X^3$ and $Z'-X'^1-X'^2-X'^3$ respectively.) Reduction of the resulting 4-nitrophenylamide or 4-nitrobenzylamide to form the corresponding 4-amino derivative imparts reactivity to the other side of Y with respect to acylation with a different acyl derivative using the methods described above.



This strategy may also be followed in cases where it is desired to combine a carbamate group on one side of Y, e.g., Y-OC(O)NHR, with an amide, -C(O)NH-, carbamate, -HNC(O)OR, or urea, -HNC(O)NRR', attached at the other side of Y (R and R' are hydrogen, Z-X¹-X²-X³ or Z'-X'¹-X'²-X'³). For example, 4-nitrophenol, 4-nitrobenzyl alcohol, or 4-nitromethylphenol may be employed in place of the aromatic groups just described to form the corresponding acylated compounds by first reacting the alcohol moiety with the first acyl group at one side of the desired molecule, followed by reduction of the nitro group to form the corresponding amine and reacting the amine with the second acyl group to complete the molecule.

Those of skill in the art will also appreciate that the units -X¹-X²-X³-X⁴- and -X'¹-X'²-X'³-X'⁴-, and their various subunits, may be formed by techniques known in the art and by analogy to the examples provided herein. It will also be appreciated that amino acids provide convenient building blocks from which to create the various functionalities which comprise the elements X¹-X⁴ and X'¹-X'⁴. The amino acids used herein include the twenty naturally occurring L-amino acids and their D- isomers as well as their derivatives. Amino acid derivatives include compounds such as norvaline, hydroxyproline, N-methyl-L-leucine, aminoisobutyric acid, statine, γ -carboxyglutamic acid, serine-O-phosphate, tyrosine-O-phosphate, tyrosine-O-sulfate, pyroglutamic acid and 4-(E)-butenyl-4-(R)-methyl-N-methyl-L-threonine. Other amino acid derivatives include the natural amino acids in which side chain functionality is derivatized or protected with common protecting groups, e.g., t-butoxycarbonyl (BOC). The techniques and methods used to synthesize, purify and evaluate such compounds are well known in the art and are described, e.g., in SYNTHETIC PEPTIDES: A USER'S GUIDE, Grant, Ed., (Freeman 1992); and SOLID PHASE PEPTIDE SYNTHESIS: A PRACTICAL APPROACH, Atherton, et al., Eds. (IRL Press 1989), both of which are incorporated herein by reference.

In some cases X³ or X'³ will be cycloheteroalkylene, e.g., pyrrolidine, piperidine, piperazine, as well as cyclic ethers, ketals, acetals and orthoesters. These groups may be

added as individual units or formed *in situ* from appropriately substituted alkylenes using standard methods, such as those described in Green and Wuts or March, *supra*.

5 The groups Z and Z' are formed readily using standard starting materials and commonly known synthetic techniques. Generally, the considerations discussed above with respect to the formation of the linkages between Y, X⁵ (X'⁵) and X⁴ (X'⁴) apply equally well to the linkages between Z (Z'), X¹ (X'¹) and X² (X'²). For example, if X¹ (X'¹) is methyl and X² (X'²) includes a nitrogen linkage to X¹ (X'¹), then p-xylylenediamine may be chosen as a starting material. One of the two aminomethyl groups may be protected as the N-butoxycarbonyl (BOC) derivative using a stoichiometric excess of p-xylylenediamine and following standard procedures (Green and 15 Wuts, *supra*). The free amino group may then be reacted with an acyl derivative to form the Z-X¹-NC(O)- portion of the molecule. The same strategy just described is applicable to the cases where Z includes a cyclohexadienyl, cyclohexenyl or cyclohexyl ring system.

20 Similar methodology is applied where X² is a carbamate (-OC(O)NR-). For example, starting from the N-BOC-protected p-xylylenediamine discussed above, reaction with N₂O₄ followed by reaction with Zn and acetic acid converts the free amine to an alcohol (Larock, *supra*; JCS Perkin I, 1114 25 (1977), which is incorporated herein by reference). The alcohol is reacted with an acyl derivative to give the desired product. The same strategy just described is applicable to the cases where Z includes a cyclohexadienyl, cyclohexenyl or cyclohexyl ring system.

30 For cases where n₁ (n'₁) is 0, the strategies discussed above may be followed using starting materials such as 4-nitrobenzylamine, 4-hydroxybenzylamine or 4-aminomethylbenzoyl chloride. These reagents are commercially available, (e.g., from Aldrich Chemical Co., Milwaukee, WI) or 35 can be synthesized using known techniques. Protection of the amine (for example, as the N-BOC derivative), is followed by conversion of nitro group to a free amine and/or reaction with an amine, alcohol or activated acyl group to attach the Z or Z'

group to the X^2 (X'^2) substituent. The same strategy just described is applicable to the cases where Z includes a cyclohexadienyl, cyclohexenyl or cyclohexyl ring system.

The guanidyl-substituted variants are formed by analogy to the methods described hereinabove. However, the aminomethyl substituent is replaced by an amino substituent which is converted to the guanidyl moiety using standard techniques such as, for example, reaction of the amine with cyanamide.

Those of skill in the art will also appreciate that the compounds of the present invention may be derived from other compounds of the invention using well-known chemical transformations.

Compounds of this invention can, depending on the nature of their functional groups, form addition salts with various inorganic and organic acids and bases. Typical inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Typical organic acids include, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like.

Salts can also be formed from a carboxylic acid residue by treatment with alkali metals or alkali metal bases, such as alkali metal hydroxides and alkali metal alkoxides, or alkaline earth metals or alkaline earth metal bases, such as alkaline earth metal hydroxides and alkaline earth metal alkoxides. In addition, salts can be formed from a carboxylic acid and an organic base, such as trimethylamine, diethylamine, ethanolamine, piperidine, isopropylamine, choline, caffeine, and the like.

The salts can be formed by conventional means, as by reacting the free acid or base forms of the product with one or more equivalents of the appropriate base or acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water, which is then removed *in vacuo* or by freeze-drying or

by exchanging the cations of an existing salt for another cation on a suitable ion exchange resin.

III. In Vitro and In Vivo Testing

In vitro protocols for screening potential inhibitors as to their ability to inhibit tryptase are known in the art. See, e.g., Sturzebecher et al. (1992) *Biol. Chem. Hoppe-Seyler* 373:1025-1030. Typically, these assays measure the tryptase-induced hydrolysis of peptide-based chromogenic substances. Details of an exemplary procedure are described below.

In addition, the activity of the compounds of the present invention can be evaluated *in vivo* in one of the numerous animal models of asthma. See Larson, "Experimental Models of Reversible Airway Obstruction", in *THE LUNG: SCIENTIFIC FOUNDATIONS*, Crystal, West et al., eds., Raven Press, New York, 1991; Warner et al. (1990) *Am. Rev. Respir. Dis.* 141:253-257. An ideal animal model would duplicate the chief clinical and physiological features of human asthma, including: airway hyperresponsiveness to chemical mediators and physical stimuli; reversal of airway obstruction by drugs useful in human asthma (β -adrenergics, methylxanthines, corticosteroids, and the like); airway inflammation with infiltration of activated leukocytes; and chronic inflammatory degenerative changes, such as basement membrane thickening, smooth muscle hypertrophy, and epithelial damage. Species used as animal models include mice, rats, guinea pigs, rabbits, dogs, and sheep. All have some limitations, and the proper choice of animal model depends upon the question which is to be addressed.

The initial asthmatic response can be evaluated in guinea pigs, and dogs, and particularly, with a basenji-greyhound cross strain which develops nonspecific airway hyperresponsiveness to numerous nonallergenic substances, such as methacholine and citric acid. Certain selected sheep exhibit a dual response after antigen challenge with *Ascaris* proteins. In dual responding animals, the initial asthmatic response (IAR) is followed by a late asthmatic response (LAR) at 6-8 hours post-exposure. Hypersensitivity to

the cholinergic agonist carbachol increases at 24 hours after antigen challenge in those animals which exhibit LAR.

5 The allergic sheep model (see below) was used to evaluate the potential antiasthmatic effects of the compounds of the present invention. Administration of compositions comprising aerosolized solutions of the compounds of the present invention to allergic sheep prior to or following exposure to specific allergens demonstrates that such compositions substantially lessen or abolish the late asthmatic response and consequent hyperresponsiveness.

10 The compounds of this invention are also useful for the treatment of other immunomediated inflammatory disorders in which tryptase activity contributes to the pathological condition. Such diseases include inflammatory diseases associated with mast cells, such as rheumatoid arthritis, conjunctivitis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, inflammatory bowel disease, peptic ulcers and various skin conditions.

15 The efficacy of the compounds of the present invention for the treatment of the vast majority of immunomediated inflammatory disorders can be evaluated by either *in vitro* or *in vivo* procedures. Thus, the anti-inflammatory efficacy of the compounds of the present invention can be demonstrated by assays well known in the art, for example, the Reversed Passive Arthus Reaction (RPAR)-PAW technique (see, e.g., Gangly et al. (1992) U.S. Patent No. 5,126,352). Assays for determining the therapeutic value of compounds in the treatment of various skin conditions, such as hyperproliferative skin disease, are well known in the art, for example, the Arachidonic Acid Mouse Ear Test (*Id.*). The compounds of the present invention can be evaluated for their antiulcer activity according to the procedures described in Chiu et al. (1984) *Archives Internationales de Pharmacodynamie et de Therapie* 270:128-140.

IV. In Vivo Administration

According to this invention, a therapeutically or pharmaceutically effective amount of a compound of the invention is administered to a patient suffering from an immunomediated inflammatory disorder. According to one embodiment, the compositions of the present invention are useful for preventing or ameliorating asthma. In using the compositions of the present invention in a treatment of asthma, the compounds may be administered prophylactically prior to exposure to allergen or other precipitating factor, or after such exposure. The compounds of the present invention are particularly useful in ameliorating the late-phase tissue destruction seen in both seasonal and perennial rhinitis. Another aspect of the present invention is directed to the prevention and treatment of other immunomediated inflammatory disorders associated with mast cells such as urticaria and angioedema, and eczematous dermatitis (atopic dermatitis), and anaphylaxis, as well as hyperproliferative skin disease, peptic ulcers, and the like.

The compositions containing the compounds can be administered for therapeutic and/or prophylactic treatments. In therapeutic applications, compositions are administered to a patient already suffering from a disease, as described above, in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective amount or dose." Amounts effective for this use will depend on the severity and course of the disease, previous therapy, the patient's health status and response to the drugs, and the judgment of the treating physician.

In prophylactic applications, compositions containing the compounds of the invention are administered to a patient susceptible to or otherwise at risk of a particular disease in an amount sufficient to prevent or ameliorate the onset of symptoms. Such an amount is defined to be a "prophylactically effective amount or dose." These can be administered orally or by inhalation. In this use, the precise amounts again depend on the patient's state of health, weight, and the like.

Once improvement of the patient's conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, can be reduced, as a function of the symptoms, to a level at which the improved condition is retained. When the symptoms have been alleviated to the desired level, treatment can cease. Patients can, however, require intermittent treatment on a long-term basis upon any recurrence of the disease symptoms.

In general, a suitable effective dose of the tryptase inhibitor will be in the range of 0.1 to 1000 milligram (mg) per recipient per day, preferably in the range of 1 to 100 mg per day. The desired dosage is preferably presented in one, two, three, four or more subdoses administered at appropriate intervals throughout the day. These subdoses can be administered as unit dosage forms, for example, containing 5 to 1000 mg, preferably 10 to 100 mg of active ingredient per unit dosage form.

The composition used in these therapies can be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, liposomes, injectable and infusible solutions. Inhalable preparations, such as aerosols, are also included. Preferred formulations are those directed to oral, intranasal and topical applications, but it will be appreciated that the preferred form will depend on the particular therapeutic application at hand. The methods for the formulation and preparation of therapeutic compositions comprising the compounds of the invention are well known in the art and are described in, for example, REMINGTON'S PHARMACEUTICAL SCIENCES and THE MERCK INDEX 11th Ed., (Merck & Co. 1989).

While it is possible to administer the active ingredient of this invention alone, it is preferable to present it as part of a pharmaceutical formulation. The formulations of the present invention comprise at least one compound or inhibitor described herein in a therapeutically or pharmaceutically effective dose together with a pharmacologically acceptable carrier. The formulation may include other clinically useful compounds, such as

β -adrenergics (e.g., albuterol, terbutaline, formoterol, fenoterol, and prenaline) and corticosteroids (e.g., beclomethasone, triamcinolone, flurisolide, and dexamethasone).

EXAMPLES

5 The following examples are provided merely for the purposes of illustration and are not to be construed in any way as limiting the scope of the present invention.

General Materials and Methods

10 The compounds described herein may be formed using techniques which are well known in the art, such as those techniques described in March, ADVANCED ORGANIC CHEMISTRY (Wiley 1992); Larock, COMPREHENSIVE ORGANIC TRANSFORMATIONS (VCH 1989); and Furniss, et al., VOGEL'S TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY 5th ed. (Longman 1989), each of which is incorporated herein by
15 reference. It will be appreciated that the syntheses described herein may require one or more protection and deprotection steps. Accordingly, the use of appropriate protecting groups is necessarily implied by the processes contained herein, although not expressly illustrated. Such protection and
20 deprotection steps may be accomplished by standard methods in addition to those described herein, such as those described in Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS (Wiley 1991), which is incorporated herein by reference.

25 Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, thin-layer chromatography or thick-layer chromatography, high-pressure liquid chromatography (HPLC), or
30 a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the examples hereinbelow. However, other equivalent separation or isolation procedures can, of course, be used.

35 Nuclear magnetic resonance (NMR) spectra were recorded on a General Electric "QE Plus" spectrometer (300

MHz). Infrared (IR) spectra were recorded on a Perkin-Elmer 1600 Fourier Transform IR (FTIR). Analytical HPLC was performed on a Ultrafast Microprotein Analyzer, Michrom BioResources, Inc. equipped with a PLRP column, 1 mm x 150 mm. Preparative HPLC was performed on a Gilson LC using a VYDAC 1 x 25 cm C₁₈ reverse phase (RP) column or a Waters Prep LC2000 system using a Vydac 5 x 25 cm C₁₈ RP column. Mass spectra (MS) were obtained on a Finnigan SSQ 710 with an ESI source by direct infusion or by HPLC MS (Ultrafast Microprotein Analyzer, C₁₈ column 2 mm X 150 mm).

Unless otherwise noted, all reagents and equipment were either prepared according to published procedures or were purchased from commercial sources, such as Aldrich Chemical Co. (Milwaukee, WI), Sigma Chemical Co. (St. Louis, MO) and ICN Chemical Co. (Irvine, CA). The techniques used to perform the syntheses described below will be recognized by those of skill in the art as routine (see, e.g., March, Larock, or Furniss *supra*).

Example 1

Bis(p-xylylenediamineglycine)-1,4-benzenedimethanol dicarbamate

Reagents and solvents were used as received from the commercial suppliers, except for dioxane which was passed through a column of basic alumina using flash chromatography techniques before use.

A solution containing 10 milliliters (mL) di-tert-butyl dicarbonate (0.044 moles (mol), 1.0 equivalents (equiv)) in dioxane (100 mL) was added dropwise to a solution of 47 grams (g) p-xylylenediamine (0.35 mol, 8.0 equiv) in dioxane (300 mL) over a period of 7 h. The resulting white suspension was stirred at 23°C for 14 h and concentrated. The residue was partitioned between ethyl acetate (three portions), water (four portions), and saturated aqueous sodium chloride. The organic layer was dried over magnesium sulfate and concentrated, providing crude N-Boc-p-xylylenediamine (9.69 g) as a pale yellow solid.

To a solution of 1.0 g *N*-Boc-*p*-xylylenediamine (4.23 mmol, 1.0 equiv) in *N,N*-dimethylformamide (25 mL) was added 0.63 g 1-hydroxybenzotriazole hydrate (4.65 mmol, 1.1 equiv), 0.88 g *N*-Cbz-glycine (4.23 mmol, 1.0 equiv), and 0.58 mL 4-methylmorpholine (5.29 mmol, 1.25 equiv). 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.89 g, 4.65 mmol, 1.1 equiv) was added to the reaction mixture at 0°C. The yellow solution was stirred at 0°C for 1 h and at 23°C for 19 h. The reaction mixture was partitioned between dichloromethane, saturated aqueous sodium bicarbonate, 0.05 N hydrochloric acid, and saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate, and concentrated to give crude *N*-CBZ-glycine-*p*-xylylenediamine-*N*-Cbz as a yellow solid.

Ethanol (50 mL) was added to a vessel holding 1.0 g of the *N*-Boc-*p*-xylylenediamine-glycine-*N*-Cbz (2.34 mmol, 1.0 equiv) and palladium on activated carbon (5%, 2.5 g, 2.5 wt equiv) under a nitrogen atmosphere. The black suspension was swept with hydrogen, and stirred under 1 atmosphere (atm) of hydrogen for 4 h. The reaction mixture was then swept with nitrogen and filtered through celite. The celite pad was washed with ethanol, dichloromethane, and 10% methanol in dichloromethane. Crude glycine-*p*-xylylenediamine-*N*-BOC was obtained as a yellow oil.

A 1.93 molar (M) solution of phosgene in toluene (50 mL, 0.097 mol, 2.7 equiv) was added to 5.0 g 1,4-benzenedimethanol (0.036 mol, 1.0 equiv) at 0°C. The reaction mixture was stirred for 19.5 hours (h), during which time the ice bath was allowed to melt, resulting in a final reaction temperature of 23°C. Nitrogen was bubbled through the yellow solution for 25 min. The solution was concentrated, giving crude 1,4-benzenedimethanol dichloroformate (8.32 g) as a yellow oil.

A solution of 0.020 mL 1,4-benzenedimethanol dichloroformate (0.12 mmol, 1.0 equiv) and pyridine (0.030 mL, 0.36 mmol, 3.0 equiv) was added to a solution of 90 mg *N*-Boc-*p*-xylylenediamine-glycine-NH₂ (0.30 mmol, 2.5 equiv) in dichloromethane (3 mL). The white suspension was stirred at

23°C for 19 h. The reaction mixture was partitioned between dichloromethane, 0.05 N hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate and concentrated to give crude bis(*N*-Boc-*p*-xylylenediamine-glycine)-1,4-benzene-
5 dimethanol-dicarbamate as a white residue.

The bis(*N*-Boc-*p*-xylylenediamine-glycine)-1,4-benzene-dimethanol dicarbamate obtained was stirred in 50% trifluoroacetic acid in dichloromethane (4 mL) at 23°C for 35
10 min. The reaction mixture was concentrated. The residue was concentrated with ether, and the solid obtained rinsed with ether (two portions) and further purified by preparative scale liquid chromatography, to give bis(*p*-xylylenediammonium-glycine)-1,4-benzenedimethanol-dicarbamate
15 bis-trifluoroacetate.

Analysis: ^1H NMR (300 MHz, CD_3OD): 7.40 (s, 12 H), 5.10 (s, 4 H), 4.40 (d, 4 H), 4.05 (s, 4 H), 3.80 (s, 4 H).
Mass Spectrum: (calcd) for $\text{C}_{30}\text{H}_{36}\text{N}_6\text{O}_6$ (M⁺): 578, found: 578.

Example 2

1,4-Benzenedimethanol bischloroformate ("bischloroformate")

1,4-benzenedimethanol (1.0 g, 7.2 mmol) was slowly added to 10 mL of a 1.9 M solution of phosgene in toluene at 0°C over several minutes. The mixture was allowed to slowly warm to room temperature with stirring under a nitrogen atmosphere for
25 an additional twelve hours. Subsequent removal of toluene *in vacuo* at room temperature provided the corresponding bischloroformate (1.7 g, 90% yield) as a colorless oil which was employed without further purification.

Analysis. ^1H -NMR (CDCl_3): 7.42 (s, 4H), 5.31 (s, 4H).

1,4-Benzenedimethanol dicarbamate-*N,N'*-acetic acid

Glycine (12.0 g, 160 mmol) was dissolved in water (100 mL) followed by the addition of sodium hydroxide (5.0 g, 125 mmol) and sodium hydrogen carbonate (5.0 g, 60 mmol).
1,4-benzenedimethanol bischloroformate (8.3 g, 31.5 mmol) was
35 subsequently added to the aqueous solution and the mixture was allowed to stir at room temperature over twelve hours. An

additional volume of water (50 mL) was added to the reaction mixture and the diluted solution filtered to remove traces of insoluble residue. The aqueous solution was acidified to a pH of 1 by dropwise addition of concentrated aqueous hydrochloric acid, and the precipitated diacid was collected by filtration. Subsequent washing with water (3 x 100 mL) and drying in vacuo provided pure biscarbamate as a colorless solid (9.5 g, 89% yield).

Analysis. $^1\text{H-NMR}$ (DMSO-d_6): 7.52 (tr, 2H), 7.31 (s, 4H), 5.02 (s, 4H), 3.65 (d, 4H).

N,N'-(4-Aminobenzylaminecarbonylmethylene)-1,4-benzenedimethanol dicarbamate

9.5 g of 1,4-benzenedimethanol dicarbamate-N,N'-acetic acid (27.9 mmol), 7.95g hydroxybenzotriazole hydrate (58.8 mmol), and 13.3 mL 4-aminobenzylamine (117.2 mmol) were dissolved in 30 mL of dimethylformamide (DMF), and the resulting yellow solution cooled to 0°C.

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (11.2 g, 58.4 mmol) was then added to the mixture which was then allowed to warm slowly to room temperature over twelve hours. Removal of the DMF in vacuo followed by the addition of water (750 mL) and filtration of the insoluble residue gave crude N,N'-(4-aminobenzylaminecarbonylmethylene)-1,4-benzenedimethanol dicarbamate as a waxy white solid. The crude material was then taken into boiling methanol (500 mL) and the resulting suspension cooled to 0°C. Filtration and drying in vacuo provided the desired product (8.0 g, 52% yield) as a colorless solid.

Analysis. $^1\text{H-NMR}$ (DMSO-d_6): 8.10 (tr, 2H), 7.40 (tr, 2H), 7.30 (s, 4H), 6.85 (d, 4H), 6.45 (d, 4H), 5.00 (s, 4H), 4.95 (br s, 4H), 4.15 (d, 4H), 3.60 (d, 4H).

N,N'-(4-Guanidylbenzylaminecarbonylmethylene)-1,4-benzenedimethanol dicarbamate

N,N'-(4-aminobenzylaminecarbonylmethylene)-1,4-benzenedimethanol dicarbamate (100 mg, 0.18 mmol) and cyanamide (1.0 g, 23.8 mmol) were heated neat at 60°C to give a slurry.

This was followed by the addition of 180 μ L of a solution of hydrogen chloride in dioxane (4 M, 0.7 millimoles (mmol)). The resulting yellow liquid was stirred at 60°C for an additional 30 minutes followed by cooling to room temperature. Addition of ethyl ether (15 mL) gave an insoluble yellow oil which was repeatedly washed with additional ethyl ether (3 x 15 mL) to remove residual cyanamide followed by drying *in vacuo*. The yellow oil was then taken into water (5 mL) and purified by preparative reverse phase HPLC to give N,N'-(4-guanidylbenzyl-aminecarbonylmethylene)-1,4-benzenedimethanol dicarbamate bis-trifluoroacetate (50 mg, 32% yield) as a colorless solid.

Analysis. $^1\text{H-NMR}$ (DMSO- d_6): 9.80 (s, 2H), 8.45 (tr, 2H), 7.50 (tr, 2H), 7.45 (s, 8H), 7.35 (s, 4H), 7.30 (d, 4H), 7.20 (d, 4H), 5.05 (s, 4H), 4.30 (d, 4H), 3.65 (d, 4H).

Electrospray LRMS: Calculated for $\text{C}_{30}\text{H}_{36}\text{N}_{10}\text{O}_6$: MH^+ : 633.7; $\text{MH}_2^{+2}/2$: 317.4. Found: MH^+ : 633.4; $\text{MH}_2^{+2}/2$: 317.2

Another synthesis of Example 2.

To a solution of 1,4-benzenedimethanol (1.40 g, 10.1 mmol) in dimethylformamide (50 mL) was added copper (I) chloride (300 mg, 3.0 mmol) followed by ethyl isocyanatoacetate (2.76 g, 21.4 mmol) and the resulting suspension was allowed to stir at room temperature over twelve hours. Water (200 mL) and dichloromethane (200 mL) were added to the mixture and the aqueous phase extracted with additional dichloromethane (200 mL). The combined organic layers were washed with water (2 x 200 mL) followed by saturated aqueous sodium chloride and dried over anhydrous magnesium sulfate. Filtration followed by concentration and drying *in vacuo* gave 1,4-benzene-dimethanol-dicarbamate-N,N'-acetic acid bis-ethyl ester (3.83 g, 96%) as a colorless solid. $^1\text{H-NMR}$ (CDCl_3): 7.40 (s, 4H), 5.30 (br s, 2H), 5.15 (s, 4H), 4.25 (q, 4H), 4.00 (d, 4H), 1.30 (tr, 6H).

To a solution of 1,4-benzenedimethanol-dicarbamate-N,N'-acetic acid bis-ethyl ester (2.87 g, 7.25 mmol) in tetrahydrofuran:methanol:water 3:1:1 (125 mL) was added sodium hydroxide (1.0 g, 25 mmol) in water (25 mL) and the mixture was allowed to stir at room temperature over four hours.

Concentration followed by acidification of the aqueous solution to pH=1 by dropwise addition of concentrated aqueous hydrochloric acid gave a white precipitate. Filtration and drying in vacuo gave 1,4-benzenedimethanol-dicarbamate-N,N'-acetic acid as a colorless solid. ¹H-NMR (DMSO-d₆): 7.52 (tr, 2H), 7.31 (s, 4H), 5.02 (s, 4H), 3.65 (d, 4H).

4-Aminobenzylamine (11.0 g, 90 mmol) in dichloromethane (30 mL) was cooled to 0°C and di-tert-butyl dicarbonate (18.65 g, 85 mmol) was added to the solution and the mixture was allowed to slowly warm to room temperature over twelve hours. Subsequent filtration followed by washing the dichloromethane solution with saturated aqueous ammonium chloride then with saturated aqueous sodium chloride, drying over anhydrous magnesium sulfate, filtration and concentration gave 4-amino-N-tert-butylcarbomoylbenzylamine as a yellow oil. A methanol solution of the aniline was acidified with hydrogen chloride in dioxane (one equivalent) and the hydrochloride salt crystallized by addition of ethyl ether to the acidic solution. Filtration and drying in vacuo provided the hydrochloride salt as a yellow crystalline solid which was guanylated without further purification.

4-Amino-N-tert-butylcarbomoylbenzylamine hydrochloride (25.77 g, 99.6 mmol) and cyanamide (55 g, 1.3 mmol) were heated neat at 65°C over 1.5 hours. The mixture was then cooled to room temperature and ether (250 mL) was added. The insoluble yellow oil was repeatedly washed with additional ethyl ether to remove traces of cyanamide and dried in vacuo to give 4-guanidyl-N-tert-butylcarbomoylbenzylamine hydrochloride as an amorphous yellow material which was carried on without further purification.

4-Guanidyl-N-tert-butylcarbomoylbenzylamine hydrochloride (14.4 g, 48 mmol) was taken up into trifluoroacetic acid (35 mL) and the resulting yellow solution stirred over 30 minutes. Concentration and drying in vacuo gave 4-guanidyl-benzylamine bis-trifluoroacetate as a yellow oil. ¹H-NMR (DMSO-d₆): 10.25 (s, 1H), 8.40 (br s, 3H), 7.65 (br s, 4H), 7.50 (d, 2H), 7.25 (d, 2H), 4.00 (d, 2H).

1,4-Benzenedimethanol-dicarbamate-N-N'-ac tic acid (5.4 g, 15.9 mmol) in dimethylformamide (30 mL) was cooled to 0°C and hydroxybenzotriazole hydrate (4.6 g, 34.0 mmol) was added followed by 1-(3-Dimethylaminopropyl)-3-ethyl-
5 carbodiimide hydrochloride (6.6 g, 34.3 mmol). The resulting mixture was stirred at 0°C over one hour then added by cannula to a slurry containing 4-guanidyl-benzylamine bis-trifluoroacetate (14.4 g, 48 mmol) and triethylamine (16.7 g, 165 mmol) in dimethylformamide (20 mL) cooled to 0°C. The
10 mixture was then allowed to slowly warm to room temperature over twelve hours followed by concentration *in vacuo*. The residue was taken into water (40 mL) and the solution pH adjusted to 11-12 by dropwise addition of saturated aqueous sodium carbonate. The white precipitate was collected by
15 filtration and the solid product taken back into aqueous solution by acidification to pH=1-2 with concentrated aqueous hydrochloric acid. Repetition of this process once followed by careful filtration of the aqueous bis-guanidine hydrochloride using Millipore filter paper type GV (0.22 µm)
20 and lyophilization gave the title compound, N,N'-(4-Guanidylbenzylamine-carbonylmethylene)-1,4-benzene-dimethanol dicarbamate bis-hydrochloride, as a colorless solid.

Example 3

N,N'-(2-Carboxyethylene)-1,4-benzenedimethanol dicarbamate

β-alanine (512 mg, 5.8 mmol) was dissolved in 3 M aqueous sodium hydroxide (3.8 mL) and the resulting solution cooled in an ice bath. 1,4-Benzenedimethanol bischlorformate (756 mg, 2.8 mmol) was added to the aqueous solution followed
30 by an additional 3.8 mL of 3 M aqueous sodium hydroxide, and the mixture was allowed to warm slowly to room temperature over twelve hours. The aqueous solution was then acidified to a pH of 1 by dropwise addition of concentrated aqueous hydrochloric acid and the precipitated diacid was collected by filtration.
35 Subsequent washing with water (3 x 20 mL) and drying *in vacuo* provided pure N,N'-(2-carboxyethylene)-1,4-benzene-dimethanol dicarbamate as a colorless solid.

Analysis. $^1\text{H-NMR}$ (DMSO-d_6): 12.20 (br s, 2H), 7.35 (s, 4H), 7.30 (tr, 2H), 5.00 (s, 4H), 3.20 (q, 4H), 2.40 (tr, 4H).

N,N'-(4-Aminobenzylaminecarbonylethylene)-1,4-benzenedimethanol dicarbamate

5 N,N'-(2-carboxyethylene)-1,4-benzenedimethanol dicarbamate (163 mg, 0.44 mmol), hydroxybenztriazole hydrate (132 mg, 0.97 mmol), and 4-aminobenzylamine (238 mg, 1.94 mmol) were dissolved in DMF (1.5 mL) and the resulting yellow
10 solution cooled to 0°C. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide-hydrochloride (187 mg, 0.97 mmol) was then added to the mixture and allowed to slowly warm to room temperature over twelve hours. Removal of DMF in vacuo followed by
15 addition of water (25 mL) and filtration of the insoluble residue gave N,N'-(4-aminobenzylaminecarbonylethylene)-1,4-benzenedimethanol dicarbamate (155 mg) as a white solid which was employed without further purification.

Analysis. $^1\text{H-NMR}$ (DMSO-d_6): 8.20 (tr, 2H), 7.35 (s, 4H), 7.25 (tr, 2H), 6.90 (d, 4H), 6.50 (d, 4H), 5.00 (s, 4H),
20 4.95 (br s, 4H), 4.05 (d, 4H), 3.20 (q, 4H), 2.30 (tr, 4H).

N,N'-(4-Aminobenzylaminecarbonylethylene)-1,4-benzenedimethanol dicarbamate

25 N,N'-(4-aminobenzylaminecarbonylethylene)-1,4-benzenedimethanol dicarbamate (155 mg, 0.27 mmol) and cyanamide (1.2 g, 28.6 mmol) were heated neat at 60°C to give a slurry followed by addition of hydrogen chloride (4 M in dioxane, 260 μL , 1.1 mmol). The resulting yellow liquid was stirred at 60°C an additional 1.5 hours followed by cooling to room
30 temperature. Addition of ethyl ether (15 mL) gave an insoluble yellow oil which was repeatedly washed with additional ethyl ether (3 x 15 mL) to remove residual cyanamide followed by drying in vacuo. The yellow oil was then taken into water (5 mL) and purified by preparative reverse phase HPLC to give
35 the desired product as the bis-trifluoroacetate salt (50 mg), a colorless solid.

Analysis. $^1\text{H-NMR}$ (DMSO-d_6): 9.82 (s, 2H), 8.42 (tr, 2H), 7.50 (tr, 2H), 7.45 (s, 8H), 7.35 (s, 4H), 7.30 (d, 4H), 7.18 (d, 4H), 5.00 (s, 4H), 4.21 (d, 4H), 3.20 (q, 4H), 2.30 (tr, 4H). Electrospray LRMS: Calculated for $\text{C}_{32}\text{H}_{40}\text{N}_{10}\text{O}_6$: MH^+ : 660.7; $\text{MH}_2^{+2}/2$: 331.4
Found: MH^+ : 661.5; $\text{MH}_2^{+2}/2$: 331.3

Example 4

Bis(L-proline- N^α -carbonyl)-1,4-dimethanolbenzene

L-proline (1.8 g, 15.6 mmol) was dissolved in water (20 mL) followed by addition of sodium hydroxide (638 mg, 15.6 mmol) and sodium hydrogen carbonate (1.0 g, 11.7 mmol). 1,4-Benzenedimethanol Bischloroformate (1.05 g, 3.9 mmol) was subsequently added to the aqueous solution and the mixture was allowed to stir at room temperature over twelve hours. An additional volume of water (50 mL) was added to the reaction mixture and the diluted solution filtered to remove traces of insoluble residue. The aqueous solution was then acidified to a pH of 1 by dropwise addition of concentrated aqueous hydrochloric acid and the precipitated bis(L-proline- N^α -carbonyl)-1,4-dimethanolbenzene collected by filtration. Subsequent washing with water (3 x 25 mL) and drying in vacuo provided pure bis(L-proline- N^α -carbonyl)-1,4-dimethanolbenzene as a colorless foam (1.29 g).

Analysis. $^1\text{H-NMR}$ (DMSO-d_6): 7.40-7.25 (4s, 4H), 5.10-5.00 (m, 4H), 4.20 (2dd, 2H), 3.45-3.30 (m, 4H), 2.30-2.10 (m, 2H), 1.95-1.75 (m, 6H).

Bis((4-aminobenzyl)-L-prolineamide- N^α -carbonyl)-1,4-dimethanolbenzene

Bis(L-proline- N^α -carbonyl)-1,4-dimethanolbenzene (498 mg, 1.18 mmol), hydroxybenztriazole hydrate (350 mg, 2.60 mmol), and 4-aminobenzylamine (560 μL , 5.0 mmol) were dissolved in DMF (5.0 mL) and the resulting yellow solution cooled to 0°C. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (498 mg, 2.60 mmol) was then added to the mixture and allowed to slowly warm to room temperature over twelve hours. Removal of DMF in vacuo followed by addition of water

(25 mL) and filtration of the insoluble residue gave bis((4-aminobenzyl)-L-prolineamide-N^α-carbonyl)-1,4-dimethanolbenzene (155 mg) as a white solid which was employed without further purification.

5 Analysis. ¹H-NMR (DMSO-d₆): 8.30-8.20 (m, 2H), 7.40-7.20 (m, 4H), 6.90-6.80 (dd, 4H), 6.50-6.40 (dd, 4H), 5.10-4.90 (m, 8H), 4.20-4.10 (m, 2H), 4.10-4.00 (m, 4H), 3.50-3.30 (m, 4H), 2.10-2.00 (m, 2H), 1.90-1.70 (m, 6H).

10 Bis((4-guanidylbenzyl)-L-prolineamide-N^α-carbonyl)-1,4-dimethanolbenzene

15 Bis((4-aminobenzyl)-L-prolineamide-N^α-carbonyl)-1,4-dimethanolbenzene (275 mg, 0.44 mmol) and cyanamide (1.04 g, 24.7 mmol) were heated neat at 60°C to give a colorless solution followed by addition of hydrogen chloride (4 M in dioxane, 430 μL, 1.76 mmol). The resulting yellow liquid was stirred at 60°C an additional 1.5 hours followed by cooling to room temperature. Addition of ethyl ether (25 mL) gave an insoluble yellow oil which was repeatedly washed with additional ethyl ether (3 x 25 mL) to remove residual cyanamide followed by drying in vacuo. The yellow oil was then taken into water (5 mL) and purified by preparative reverse phase HPLC to give the bis-trifluoroacetate salt of the desired product as a colorless solid.

20 Analysis. ¹H-NMR (DMSO-d₆): 9.80 (s, 2H), 8.60-8.50 (m, 2H), 7.42 (s, 8H), 7.40-7.05 (m, 12H), 5.10-4.95 (m, 4H), 4.30-4.20 (m, 6H), 3.50-3.30 (m, 4H), 2.20-2.10 (m, 2H), 1.90-1.75 (m, 6H). Electrospray LRMS: Calculated for C₃₆H₄₄N₁₀O₆: MH⁺: 713.8; MH₂⁺²/2: 357.4. Found: MH⁺: 713.9; MH₂⁺²/2: 357.5.

30 Example 5

Bis(L-alanine-N^α-carbonyl)-1,4-dimethanolbenzene

 L-alanine (1.47g, 16.5 mmol) was dissolved in water (20 mL) followed by addition of sodium hydroxide (662 mg, 16.5 mmol) and sodium hydrogen carbonate (1.0 g, 11.7 mmol). Bischloroformate (1.12 g, 4.25 mmol) was subsequently added to the aqueous solution and the mixture was allowed to stir at

room temperature over twelve hours. An additional volume of water (50 mL) was added to the reaction mixture and the diluted solution filtered to remove traces of insoluble residue. The aqueous solution was then acidified to a pH of 1 by dropwise addition of concentrated aqueous hydrochloric acid and the precipitated diacid bis(L-alanine-N α -carbonyl)-1,4-dimethanolbenzene collected by filtration. Subsequent washing with water (3 x 25 mL) and drying *in vacuo* provided pure bis(L-alanine-N α -carbonyl)-1,4-dimethanolbenzene as a colorless solid.

Analysis. $^1\text{H-NMR}$ (DMSO- d_6): 7.60 (d, 2H), 7.35 (s, 4H), 5.01 (s, 4H), 4.00 (m, 2H), 1.25 (d, 6H)

--
Bis((4-aminobenzyl)-L-alanineamide-N α -carbonyl)-
1,4-dimethanolbenzene

Bis(L-alanine-N α -carbonyl)-1,4-dimethanolbenzene (392 mg, 1.06 mmol), hydroxybenztriazole hydrate (300 mg, 2.23 mmol), and 4-aminobenzylamine (500 μL , 4.24 mmol) were dissolved in DMF (5.0 mL) and the resulting yellow solution cooled to 0°C. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (427 mg, 2.23 mmol) was then added to the mixture and allowed to slowly warm to room temperature over twelve hours. Removal of DMF *in vacuo* followed by addition of water (25 mL) and filtration of the insoluble residue gave bis((4-aminobenzyl)-L-alanineamide-N α -carbonyl)-1,4-dimethanolbenzene as a white solid which was employed without further purification.

Analysis. $^1\text{H-NMR}$ (DMSO- d_6): 8.10 (tr, 2H), 7.35 (d, 2H), 7.30 (s, 4H), 6.85 (d, 4H), 6.45 (d, 4H), 5.00 (s, 4H), 4.05 (d, 4H), 4.00 (m, 2H), 1.20 (d, 6H).

Bis((4-guanidylbenzyl)-L-alanineamide-N α -carbonyl)-
1,4-dimethanolbenzene

Bis((4-aminobenzyl)-L-alanineamide-N α -carbonyl)-1,4-dimethanolbenzene (121 mg, 0.22 mmol) and cyanamide (580 mg, 13.8 mmol) were heated neat at 60°C to give a colorless solution followed by addition of hydrogen chloride (4 M in dioxane, 220 μL , 0.88 mmol). The resulting yellow liquid was stirred at 60°C an additional 2.0 hours followed by

cooling to room temperature. Addition of ethyl ether (25 mL) gave an insoluble yellow oil which was repeatedly washed with additional ethyl ether (3 x 25 mL) to remove residual cyanamide followed by drying in vacuo. The yellow oil was then taken
5 into water (5 mL) and purified by preparative reverse phase HPLC to give the desired product as a bis-trifluoroacetate salt, a colorless solid.

Analysis. $^1\text{H-NMR}$ (DMSO- d_6): 9.75 (s, 2H), 8.40 (tr, 2H), 7.41 (d, 2H), 7.40 (s, 8H), 7.30 (s, 4H), 7.25 (d, 4H),
10 7.15 (d, 4H), 5.00 (dd AB, 4H), 4.25 (d, 4H), 4.05 (m, 2H), 1.20 (d, 6H). Electrospray LRMS: Calculated for $\text{C}_{32}\text{H}_{40}\text{N}_{10}\text{O}_6$: MH^+ : 661.7; $\text{MH}_2^{+2}/2$: 331.4. Found: MH^+ : 661.6; $\text{MH}_2^{+2}/2$: 331.5

Example 6

Bis(D-alanine- N^α -carbonyl)-1,4-dimethanolbenzene

D-alanine (1.58 g, 17.8 mmol) was dissolved in water (20 mL) followed by addition of sodium hydroxide (711 mg, 17.8 mmol) and sodium hydrogen carbonate (1.1 g, 13.4 mmol). Bischloroformate (1.15 g, 4.36 mmol) was subsequently added to
20 the aqueous solution and the mixture was allowed to stir at room temperature over twelve hours. An additional volume of water (50 mL) was added to the reaction mixture and the diluted solution filtered to remove traces of insoluble residue. The aqueous solution was then acidified to a pH of 1 by dropwise
25 addition of concentrated aqueous hydrochloric acid and the precipitated diacid bis(D-alanine- N^α -carbonyl)-1,4-dimethanolbenzene collected by filtration. Subsequent washing with water (3 x 25 mL) and drying in vacuo provided pure
30 bis(D-alanine- N^α -carbonyl)-1,4-dimethanolbenzene as a colorless solid.

Analysis. $^1\text{H-NMR}$ (DMSO- d_6): 7.60 (d, 2H), 7.35 (s, 4H), 5.01 (s, 4H), 4.00 (m, 2H), 1.25 (d, 6H)

Bis((4-aminobenzyl)-D-alanineamide- N^α -carbonyl)-1,4-dimethanolbenzene

D-alanine derived diacid bis(D-alanine- N^α -carbonyl)-

1,4-dimethanolbenzene (390 mg, 1.05 mmol), hydroxybenztriazole hydrate (300 mg, 2.23 mmol), and 4-aminobenzylamine (500 μ L, 4.24mmol) were dissolved in DMF (5.0mL) and the resulting yellow solution cooled to 0°C. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (427 mg, 2.23 mmol) was then added to the mixture and allowed to slowly warm to room temperature over twelve hours. Removal of DMF *in vacuo* followed by addition of water (25 mL) and filtration of the insoluble residue gave bis((4-aminobenzyl)-D-alanineamide-N α -carbonyl)-1,4-dimethanolbenzene as a white solid which was employed without further purification.

Analysis. $^1\text{H-NMR}$ (DMSO- d_6): 8.10 (tr, 2H), 7.35 (d, 2H), 7.30 (s, 4H), 6.85 (d, 4H), 6.45 (d, 4H), 5.00 (s, 4H), 4.05 (d, 4H), 4.00 (m, 2H), 1.20 (d, 6H).

Bis((4-aminobenzyl)-D-alanineamide-N α -carbonyl)-
1,4-dimethanolbenzene

Bis((4-aminobenzyl)-D-alanineamide-N α -carbonyl)-1,4-dimethanolbenzene (121 mg, 0.22 mmol) and cyanamide (570 mg, 13.6mmol) were heated neat at 60°C to give a colorless solution followed by addition of hydrogen chloride (4 M in dioxane, 220 μ L, 0.88 mmol). The resulting yellow liquid was stirred at 60°C an additional 1.5 hours followed by cooling to room temperature. Addition of ethyl ether (25 mL) gave an insoluble yellow oil which was repeatedly washed with additional ethyl ether (3 x 25 mL) to remove residual cyanamide followed by drying *in vacuo*. The yellow oil was then taken into water (5 mL) and purified by preparative reverse phase HPLC to give the desired product as the bis-trifluoroacetate salt, a colorless solid.

Analysis. $^1\text{H-NMR}$ (DMSO- d_6): 9.75 (s, 2H), 8.40 (tr, 2H), 7.41 (d, 2H), 7.40 (s, 8H), 7.30 (s, 4H), 7.25 (d, 4H), 7.15 (d, 4H), 5.00 (dd AB, 4H), 4.25 (d, 4H), 4.05 (m, 2H), 1.20 (d, 6H). Electrospray LRMS: Calculated for $\text{C}_{32}\text{H}_{40}\text{N}_{10}\text{O}_6$: MH^+ : 661.7; $\text{MH}_2^{+2}/2$: 331.4
Found: MH^+ : 661.6; $\text{MH}_2^{+2}/2$: 331.5

Example 7

Bis(L-phenylalanine-N^α-carbonyl)-1,4-dimethanolbenzene

L-Phenylalanine (2.52 g, 15.3 mmol) was dissolved in water (20 mL) followed by addition of sodium hydroxide (610 mg, 15.3 mmol) and sodium hydrogen carbonate (1.28 g, 11.5 mmol). Bischloroformate (1.0 g, 3.8 mmol) was subsequently added to the aqueous solution and the mixture was allowed to stir at room temperature over twelve hours. An additional volume of water (50 mL) was added to the reaction mixture and the diluted solution filtered to remove traces of insoluble residue. The aqueous solution was then acidified to pH = 1 by dropwise addition of concentrated aqueous hydrochloric acid and the precipitated diacid bis(L-phenylalanine-N^α-carbonyl)-1,4-dimethanolbenzene collected by filtration. Subsequent washing with water (3 x 25 mL) and drying in vacuo provided pure bis(L-phenylalanine-N^α-carbonyl)-1,4-dimethanolbenzene as a colorless solid.

Analysis. ¹H-NMR (DMSO-d₆): 7.68 (d, 2H), 7.30-7.15 (m, 14H), 4.95 (dd AB, 4H), 4.22-4.12 (m, 2H), 3.05 (dd, 2H), 2.80 (dd, 2H).

Bis((4-aminobenzyl)-L-phenylalanineamide-N^α-carbonyl)-1,4-dimethanolbenzene

L-phenylalanine derived bis(L-phenylalanine-N^α-carbonyl)-1,4-dimethanolbenzene (507 mg, 0.97 mmol), hydroxybenztriazole hydrate (299 mg, 2.21 mmol), and 4-aminobenzylamine (460 μL, 4.1 mmol) were dissolved in DMF (5.0 mL) and the resulting yellow solution cooled to 0°C. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (415 mg, 2.17 mmol) was then added to the mixture and allowed to slowly warm to room temperature over twelve hours. Removal of DMF in vacuo followed by addition of water (25 mL) and filtration of the insoluble residue gave bis((4-aminobenzyl)-L-phenylalanineamide-N^α-carbonyl)-1,4-dimethanolbenzene as a white solid which was employed without further purification.

Analysis. ¹H-NMR (DMSO-d₆): 8.30 (tr, 2H), 7.50 (d, 2H), 7.30-7.10 (m, 14H), 6.85 (d, 4H), 6.50 (d, 4H), 4.95

(br s, 8H), 4.30-4.20 (m, 2H), 4.10 (d, 4H), 2.95 (dd, 2H), 2.75 (dd, 2H).

Bis(4-guanidylbenzyl)-L-phenylalanineamide-N^α-carbonyl)-
1,4-dimethanolbenzene

5 Bis((4-aminobenzyl)-L-phenylalanineamide-N^α-carbonyl)-1,4-dimethanolbenzene (249 mg, 0.32 mmol) and cyanamide (1.15 g, 27.4 mmol) were heated neat at 60°C to give a colorless solution followed by addition of hydrogen chloride (4 M in dioxane, 320 μL, 1.28 mmol). The resulting yellow
10 liquid was stirred at 60°C an additional 1.5 hours followed by cooling to room temperature. Addition of ethyl ether (25 mL) gave an insoluble yellow oil which was repeatedly washed with additional ethyl ether (3 x 25 mL) to remove residual cyanamide followed by drying in vacuo. The yellow oil was then taken
15 into water (5 mL) and purified by preparative reverse phase HPLC to give the desired product as a bis-trifluoroacetate salt, a colorless solid.

 Analysis. ¹H-NMR (DMSO-d₆): 9.70 (s, 2H), 8.60 (tr, 2H), 7.58 (d, 2H), 7.40 (s, 8H), 7.30-7.10 (m, 14H), 4.90 (dd
20 AB, 4H), 4.30-4.20 (m, 6H), 2.95 (dd, 2H), 2.75 (dd, 2H).
Electrospray LRMS: Calculated for C₄₄H₄₈N₁₀O₆: MH⁺: 813.9; MH₂⁺²/2: 407.5. Found: MH⁺: 814.0; MH₂⁺²/2: 407.6

Example 8

N,N'-bis(N-(4-aminomethylbenzyl)-
25 succinamido)-p-xylylenediamide

 A solution of dimethyl succinate (1.46 gm, 10.72 mmol) and p-xylylenediamine (7.9 gm, 54 mmol) was allowed to stir overnight at room temperature (R.T.) then heated to 90°C for 16 h. The reaction mixture was cooled, diluted with EtOAc and
30 washed with 1N HCl. The organic layer was dried and concentrated to a yellow solid. The solid was washed with hexanes twice and dried in vacuo. The diamide (0.05 gm, 0.137 mmol) and p-xylylene diamine (0.187 gm, 1.37 mmol) were heated at 67°C for 48 h. The solid residue was mixed with
35 water and stirred vigorously. The suspension was centrifuged, and the water decanted. Another portion of water was added and

the residue stirred and centrifuged. The water was decanted, and MeOH was added. The material was stirred and centrifuged, the MeOH decanted. The residue was dried to an off-white solid. This was dissolved in HOAc and precipitated with EtOAc. The desired compound was purified by prep HPLC, 30 mg at a time, 4 injections (2-27% ACN/water). A single peak was collected and lyophilized to a white solid (90 mg).

Example 9

N,N'-Bis(N-(4-aminomethylbenzyl)-malonamido)-p-xylylene diamide

p-Xylylene diamine (1.0g, 7.4 mmol) was melted at 67°C. Diethyl malonate (0.372 mL, 2.5 mmol) was added with stirring. The mixture was stirred at 67°C under nitrogen atmosphere overnight (ca. 18 h). Water (30 mL) was added and this mixture was stirred briefly. The mixture was centrifuged at 1500 rpm for 10 min and the water was decanted. Water (25 mL) was added and this mixture was stirred briefly. The mixture was centrifuged for 10 min and the water was decanted. Acetic acid (10 mL) and diethyl ether (40 mL) were added. The mixture was centrifuged for 10 minutes. The liquid was decanted. Diethyl ether (10 mL) was added, the mixture was stirred, and the ether was decanted. The compound was dried under vacuum. From the residue, 30 mg was separated by preparatory liquid chromatography (Prep LC) on a 5-30% ACN/Water 0.1% TFA gradient over 30 min to yield 6 mg of the bis-TFA salt of the title compound.

Analysis. ¹H NMR (CDCl₃) δ 7.4(s), 7.3(s), 4.45(s), 4.40(s), 4.35(s), 4.1(s), 3.3(s). Calculated mass for C₃₀H₃₆N₆O₄: 544.3236, found [M+1]=545.8 and [M+2]/2=273.5.

Example 10

N,N'-Bis(N-aminomethylbenzyl)glutaramido)-p-xylylene diamide

p-Xylylene diamine (1.0g, 7.4 mmol) was heated to 67°C. Dimethyl glutarate (0.36 mL, 2.5 mmol) was added with stirring. The mixture was stirred at 67°C under nitrogen atmosphere overnight (ca. 18 h). Water (30 mL) was added and this mixture was stirred briefly. The mixture was centrifuged

at 1500 rpm for 10 min and the water was decanted. Water (30 mL) was added and this mixture was stirred briefly. The mixture was centrifuged for 10 min and the water was decanted. Acetic acid (5 mL) and diethyl ether (40 mL) were added. The mixture was centrifuged for 10 minutes. The liquid was decanted. Diethyl ether (10 mL) was added, the mixture was stirred, and the ether was decanted. The compound was dried under vacuum. From the residue, 30 mg was separated by PrepLC on a 5-30% ACN/Water 0.1% TFA gradient over 30 min to yield 5 mg of the bis-TFA salt of the title compound.

From the peak at 22.1 min, the desired compound was characterized: ^1H NMR (CDCl_3) δ 7.21(d, J=3 Hz), 7.19(d, J=3 Hz), 4.25(s), 4.21(s), 3.96 (s), 2.17(m), 1.80(m). Calculated mass for $\text{C}_{34}\text{H}_{44}\text{N}_6\text{O}_4$: 600.3872, found $[\text{M}+1]=601.8$ and $[\text{M}+2]/2=301.5$.

Example 11

N,N'-Bis(N-(3-aminomethylbenzyl)succinamido)-m-xylylene diamide

m-Xylylene diamine (1.0 g, 7.4 mmol) was stirred at room temperature. Dimethyl succinate (0.320 mL, 2.5 mmol) was added with stirring. The mixture was stirred at room temperature over weekend (ca. 66 h). Water (25 mL) was added and this mixture was stirred briefly. The mixture was centrifuged at 1500 rpm for 10 min and the water was decanted. Water (25 mL) was added and this mixture was stirred briefly. The mixture was centrifuged for 10 min and the water was decanted. Acetic acid (5 mL) and diethyl ether (40 mL) were added. The mixture was centrifuged for 10 minutes. The liquid was decanted. Diethyl ether (10 mL) was added, the mixture was stirred, and the ether was decanted. The compound was dried under vacuum. From the residue, 30 mg was separated by PrepLC on a 0-25% ACN/Water 0.1% TFA gradient over 30 min to yield 3 mg of the bis-TFA salt of the title compound.

From the peak at 34.4 min, the desired compound was characterized: ^1H NMR (D_2O) δ 7.2(m), 4.35(s), 4.25(s), 4.05(s), 2.6(s). Calculated mass for $\text{C}_{32}\text{H}_{40}\text{N}_6\text{O}_4$: 572.3554, found $[\text{M}+1]=573.7$ and $[\text{M}+2]/2=287.5$.

Exempl 12

N,N'-Bis(N-(4-aminomethylbenzamido)-4-aminobutyric)-p-xylylene diamide

To a solution of 4-aminobutyric acid (440 mg, 4.3 mmol, 1.0 equiv) and sodium hydroxide (188 mg, 4.7 mmol, 1.1 equiv) in THF (25 mL) and water (25 mL) was added benzyl chloroformate (0.630 mL, 4.4 mmol, 1.0 equiv). After 45 min, more sodium hydroxide (175 mg, 4.4 mol, 1.0 equiv) was added. The solution was stirred for 3 h and concentrated in vacuo. Water was added, and the mixture was washed three times with dichloromethane, three times with ethyl acetate, and concentrated.

To the residue (416 mg) in dichloromethane (20 mL) was added p-xylylene diamine (116 mg, 0.85 mmol, 0.48 equiv) and DMF (3 mL). The solution was cooled to 0°C, and hydroxybenzotriazole hydrate (HOBT, 243 mg, 1.8 mmol, 1.0 equiv) and Dimethylaminopropylethyl carbodiimide HCl (EDC, 338 mg, 1.8 mmol, 1.0 equiv) were added. N-Methyl morpholine (NMM, 30 drops) was added, and the solution was stirred at 0°C for 1 h and overnight at room temperature. Dichloromethane was added and the solution was washed with 0.2 N HCl. A precipitate was filtered from the acid layer.

To this precipitate was added ethanol and palladium (5% on carbon, 238 mg). The mixture was stirred under hydrogen (1 atm) overnight. The mixture was filtered and the ethanol layer was concentrated in vacuo to yield crude diamide.

To a solution of di-tert-butyl dicarbonate (1.2 g, 8.0 mmol, 1 equiv) in tetrahydrofuran (15 mL) was added a solution of 4-(aminomethyl)benzoic acid (1.9 g, 8.7 mmol, 1.1 equiv) in tetrahydrofuran (35 mL). The solution was stirred for 24 hours. The solution was concentrated in vacuo. Water (50 mL) was added and decanted. A solution of 0.1N HCl was added (50 mL). The product, N-Boc-4-(aminomethyl)benzoic acid was removed by filtration and dried in vacuo.

To the crude diamide (227 mg) in DMF (10 mL) at 0°C were added HOBT (228 mg, 1.7 mmol, 2.3 equiv), EDC (324 mg, 1.7 mmol, 2.3 equiv), N-Boc-4-(aminomethyl)benzoic acid (311 mg, 1.3 mmol, 1.8 equiv), and NMM (30 drops). The solution was

stirred at 0°C for 20 min and at 50°C overnight. The solution was washed with 0.1N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated *in vacuo*.

5 To 100 mg of the crude compound was added dichloromethane (10 mL) and TFA (10 mL). The solution was stirred for 1 h and concentrated *in vacuo*. The residue was rinsed twice with ether and dried under vacuum. The crude product was purified on Waters LC (2-30% acetonitrile in water) and further purified on Gilson LC (2-27% acetonitrile in water) to yield 2 mg of >95% pure bis-TFA salt of the title compound.

10 Analysis. ¹H NMR (D₂O): 7.6 (d, J=9 Hz, 4H), 7.4 (d, J=9 Hz, 4H), 7.1 (s, 4H), 4.2 (s, 4H), 4.15 (s, 4H), 3.3 (t, J=7 Hz, 4H), 2.3 (t, J=7 Hz, 4H), 1.9 (m, 4H). Mass Spectrum: 15 calcd mass for C₃₂H₄₀N₆O₄: 572.3554, found: [M+1]=537.5, [M+2]/2=287.3.

Example 13

Bis(p-xylylenediamine-L-alanine)- 1,4-benzenedimethanol dicarbamate

20 To a solution of p-xylylene diamine (5.4 g, 40 mmol, 8 equiv) in 1,4-dioxane (50 mL) was added dropwise a solution of Boc anhydride (1.09 g, 5 mmol, 1 equiv) in 1,4-dioxane (30 mL). The solution was stirred for 3 days. The solvent was removed *in vacuo*. The residue was dissolved in water and 25 filtered. The aqueous layer was extracted with dichloromethane (4 x 25 mL). The combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Dichloromethane (50 mL) was added. The solution was washed with water (3 x 50 mL), dried over MgSO₄, filtered, and concentrated *in vacuo* 30 to yield mono-Boc xylylene diamine.

To a solution of mono-Boc xylylene diamine (116 mg, 0.49 mmol, 2.2 equiv) in dichloromethane (20 mL) at 0°C was added previously synthesized L-alanine-benzenedimethanol dicarbamate (80 mg, 0.22 mmol, 1 equiv), EDC (94 mg, 0.49 mmol, 2.2 equiv), and HOBT (72 mg, 0.53 mmol, 2.4 equiv). NMM (30 35 drops) and DMF (1 mL) were added. The solution was stirred at 0°C for 1 hour and at r.t. overnight. The solution was washed

with 0.1N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was concentrated *in vacuo*. TFA and dichloromethane (10 mL each) were added and the solution was stirred for ~1/2 h. The solution was concentrated under vacuum and rinsed twice with ether. The crude product was purified on the Waters LC (2-30% gradient) to yield >24 mg of >96% pure bis HCl salt of the title compound.

Analysis. ¹H NMR (D₂O) δ 7.4-7.2 (m, 12H), 5.1 (s, 4.4H), 4.4-4.0 (m, 10.7H) 1.3 (broad s, 6.3H). Mass Spectrum: calcd mass for C₂₂H₄₀N₆O₆, 604.7062, found [M+1]=605.8, [M+2]/2=303.6.

Example 14

Bis(p-xylylenediamine-D-alanine)-1,4-benzenedimethanol dicarbamate

This compound was prepared in the same manner as described in Example 13, except using D-alanine-benzenedimethanol.

Example 15

N,N'-Bis(N-(4-aminomethylbenzyl)butyramido)terephthalamide

Benzyl chloroformate (0.630 mL, 753 mg, 4.4 mmol, 1 equiv) and 4-aminobutyric acid (440 mg, 4.3 mmol, 1 equiv) were added to a solution of NaOH (188 mg, 4.7 mmol, 1.1 equiv) in THF-water (25 mL each). More NaOH (175 mg, 4.4 mmol, 1 equiv) was added to make pH>7. The solution was stirred for 3 h. The solution was concentrated *in vacuo*. Water was added and the solution was washed three times each with dichloromethane and ethyl acetate. The aqueous layer was concentrated *in vacuo* to yield N-Cbz-4-aminobutyric acid. To a solution of mono-Boc p-xylylene diamine (271 mg, 1.1 mmol, 1 equiv) in dichloromethane (25 mL) was added N-Cbz-4-aminobutyric acid (258 mg, 1.1 mmol, 1 equiv). The mixture was cooled to 0°C. HOBT (165 mg, 1.2 mmol, 1.1 equiv) and EDC (233 mg, 1.2 mmol, 1.1 equiv) were added. NMM (30 drops) was added to adjust pH. The solution was stirred at 0°C for 1 h and at r.t. over the weekend. Dichloromethane was added, and the solution was washed with 0.05N HCl, saturated aqueous sodium bicarbonate,

and brine. The organic layer was dried over MgSO_4 , filtered, and concentrated *in vacuo*. Ethanol (30 mL) and palladium (270 mg, 5%/C) were added to the residue (432 mg) and the mixture was stirred under hydrogen (1 atm) for 20 h. The mixture was filtered, and the ethanol was removed *in vacuo*. To the residue (206 mg, 0.64 mmol, 2.1 equiv) was added dichloromethane (25 mL) and DMF (2 mL). Triethylamine (0.091 mL, 66 mg, 0.65 mmol, 2.2 equiv) and terephthaloyl dichloride (60 mg, 0.3 mmol, 1 equiv) were added and the solution was stirred overnight. The solution was washed with 0.05N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was concentrated *in vacuo*. TFA and dichloromethane (10 mL each) were added and the solution was stirred for 1 h. The solution was concentrated under vacuum and rinsed twice with ether. The crude product was purified on the Waters LC (2-30% gradient) to yield 50 mg of >95% pure bis TFA salt of the title compound.

Analysis. ^1H NMR (D_2O) δ 7.7 (s, 4H), 7.3 (d, $J=9$ Hz, 4H), 7.2 (d, $J=9$ Hz, 4H), 4.2 (s, 4H), 4.0 (s, 4H), 3.4 (t, $J=6$ Hz, 4H), 2.4 (t, $J=6$ Hz, 4H), 1.9 (m, 4H). Mass Spectrum: calcd mass for $\text{C}_{22}\text{H}_{26}\text{N}_6\text{O}_4$, 572.7074, found $[\text{M}+1]=573.7$, $[\text{M}+2]/2=286.2$.

Example 16

N,N'-Bis(4-aminomethylbenzamidoethylene)- 1,4-benzenedimethanol dicarbamate

Ethylene diamine (2.67 mL, 2.4 g, 40 mmol, 8 equiv) was dissolved in basic alumina-filtered dioxane (40 mL). Boc anhydride (1091 mg, 5 mmol, 1 equiv) in dioxane (30 mL) was added dropwise. The solution was stirred for 24 h. The solution was concentrated *in vacuo*. The residue was dissolved in water and filtered. The aqueous layer was extracted three times with dichloromethane. The combined organic layers were dried over MgSO_4 , filtered, and concentrated *in vacuo* to yield an oil. The mono-Boc ethylene diamine (210 mg, 1.3 mmol, 2.2 equiv) was dissolved in dichloromethane (12 mL). Triethylamine (0.199 mL, 144 mg, 1.4 mmol, 2.4 equiv) and previously-synthesized 1,4-benzyl dichloroformate (0.108 mL,

158 mg, 0.6 mmol, 1 equiv) were added. The solution was stirred for 3 days. The solution was washed with 0.015N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was concentrated in vacuo. The residue was dissolved in 10 mL each of TFA and dichloromethane and stirred for 1 h. The solution was concentrated in vacuo and the residue was rinsed twice with ether. The product (277 mg, 0.52 mmol, 1 equiv) was dissolved in dichloromethane. P-Boc-aminomethyl benzoic acid (380 mg, 1.5 mmol, 2.9 equiv) was added. HOBT (211 mg, 1.6 mmol, 3 equiv) and EDC (296 mg, 1.5 mmol, 2.9 equiv) were added. DMF (1 mL) and NMM (30 drops) were added. The solution was stirred at 50°C overnight. The solution was washed with 0.015N HCl, saturated aqueous sodium bicarbonate, and brine. The solution was concentrated in vacuo. The residue was dissolved in 10 mL each of TFA and dichloromethane and stirred for 2 h. The solvent was removed in vacuo and the residue was rinsed twice with ether. The crude product was purified on the Waters LC (2-30% gradient) to yield 5 mg of >95% pure bis TFA salt of the title compound.

Analysis. ¹H NMR (D₂O) δ 7.6 (d, J=7 Hz, 4H), 7.4 (d, J=7 Hz, 4H), 7.1 (s, 4H), 4.95 (s, 4H), 4.2 (s, 4H), 3.4 (m, 4H), 3.3 (m, 4H). Mass Spectrum: calcd mass for C₃₀H₃₆N₆O₆, 576.6524, found [M+1]=577.7, [M+2]/2=289.0.

Example 17

N,N'-Bis(N-(4-aminomethylbenzyl)glutaramido)-N,N'-bis(methyl)-p-xylylene diamide

Mono-Boc xylylene diamine (359 mg, 1.5 mmol, 1 equiv) was dissolved in dichloromethane (15 mL). Triethylamine was added (0.230 mL, 167 mg, 1.65 mmol, 1.1 equiv). Methyl glutaryl chloride (0.208 mL, 248 mg, 1.5 mmol, 1 equiv) was added. The solution was stirred for 3 days. The solution was washed with 25 mL each of 0.015N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo. The residue (570 mg, 1.5 mmol, 1 equiv) was dissolved in methanol (15 mL). Ba(OH)₂ (538 mg, 1.7 mmol, 2.2 equiv) was added. The solution was stirred overnight. A solution of 1N HCl (25 mL) was added

to the reaction mixture. The product was extracted three times with dichloromethane. The solvent was removed *in vacuo* to yield the carboxylic acid (373 mg). The carboxylic acid (179 mg, 0.51 mmol, 1 equiv) was dissolved in dichloromethane (10 mL). N,N'-bis-methyl xylylene diamine (111 mg, 0.28 mmol, 0.55 equiv) was added. The solution was cooled to 0°C. DMF (1 mL) was added. EDC (114 mg, 0.59 mmol, 1.2 equiv), HOBT (76 mg, 0.56 mmol, 1.1 equiv), and NMM (30 drops) were added. The solution was stirred at 0°C for 1 h, and at r.t. for 2 days. The solution was washed with 0.015N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over-MgSO₄, filtered, and concentrated *in vacuo*. The residue was dissolved in TFA (10 mL) and dichloromethane (10 mL) and stirred for 45 min. The solution was concentrated *in vacuo*. The crude product was purified on the Waters LC (2-30% gradient) to yield 40 mg of >95% pure bis TFA salt of the title compound.

Analysis. ¹H NMR (D₂O) δ 7.4-7.1 (m, 12H), 4.6-4.0 (m, 12H), 2.9 (s, 6H), 2.4-2.2 (m, 8H), 1.9 (m, 4H). Mass Spectrum: calcd mass for C₃₀H₂₈N₆O₆, 628.8149, found [M+1]=629.8.

Example 18

Bis(p-xylylenediaminesarcosine)-1,4-benzenedimethanol dicarbamate

Sarcosine methyl ester (187 mg, 1.3 mmol, 2.2 equiv) was dissolved in dichloromethane. Triethylamine (0.400 mL, 290 mg, 2.9 mmol, 4.8 equiv) and 1,4-benzyl dichloroformate (0.108 mL, 158 mg, 0.6 mmol) were added. The solution was stirred for 3 days. The solution was washed with 50 mL each of 0.1N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over MgSO₄, filtered, and concentrated *in vacuo*. The residue (175 mg, 0.44 mmol) was added to p-xylylene diamine (1.750 g, 12.9 mmol, 14.7 equiv). The mixture was heated to 70°C overnight. Water was added. The mixture was centrifuged at 2000 rpm for 10 min and the water was decanted. The trituration was repeated with water, acetic acid-ether, and ether. The residue was concentrated *in vacuo*. The crude product was purified on the Waters LC (2-30%

gradient) to yield 66 mg of >95% pure bis TFA salt of the title compound.

Analysis. ¹H NMR (D₂O) δ 7.4-7.1 (m, 12H), 5.0 (s, 3.2H), 4.4-3.9 (m, 11.3H), 2.9 (s, 5.3H). Mass Spectrum: calcd mass for C₂₂H₄₀N₆O₆, 604.7062, found [M+1]=605.4, [M+2]/2=303.3.

Example 19

N,N'-Bis(4-aminomethylbenzamidopropylene)- 1,4-benzenedimethanol dicarbamate

10 Diaminopropane (3.332 mL, 2.959 g, 40 mmol, 6.9 equiv) was dissolved in basic alumina-filtered dioxane (40 mL). Boc anhydride (1272 mg, 5.8 mmol, 1 equiv) in dioxane (60 mL) was added dropwise. The solution was stirred for 3 days. The solution was concentrated in vacuo. The residue was dissolved
15 in water and filtered. The aqueous layer was extracted three times with dichloromethane. The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo to yield an oil. The mono-Boc diaminopropane (248 mg, 1.4 mmol, 2.3 equiv) was dissolved in dichloromethane (12 mL). Triethylamine (0.220 mL,
20 160 mg, 1.6 mmol, 2.6 equiv) and previously-synthesized 1,4-benzyl dichloroformate (0.112 mL, 164 mg, 0.62 mmol, 1 equiv) were added. The solution was stirred overnight. The solution was washed with 0.1 N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over
25 MgSO₄, filtered, and concentrated in vacuo to yield a white powder. The powder was dissolved in 10 mL each of TFA and dichloromethane and stirred for 45 min. The solution was concentrated in vacuo and the residue was rinsed twice with ether. The product (122 mg, 0.21 mmol, 0.5 equiv) was
30 dissolved in dichloromethane (20 mL). P-Boc-aminomethyl benzoic acid (105 mg, 0.42 mmol, 1 equiv) was added. HOBT (66 mg, 0.49 mmol, 1.2 equiv) and EDC (92 mg, 0.48 mmol, 1.1 equiv) were added. DMF (2 mL) and NMM (30 drops) were added. The solution was stirred at 0°C for 30 min, 50°C overnight, and
35 r.t. for 3 days. The solution was washed with 0.1N HCl, saturated aqueous sodium bicarbonate, and brine. The solution was concentrated in vacuo. The residue was dissolved in 10 mL

each of TFA and dichloromethane and stirred for 30 min. The solvent was removed in vacuo and the residue was rinsed twice with ether. The crude product was purified on the Waters LC (2-30% gradient) to yield 20 mg of >95% pure bis TFA salt of the title compound.

Analysis. ^1H NMR (D_2O) δ 7.7 (d, $J=9$ Hz, 4H), 7.5 (d, $J=9$ Hz, 4H), 7.3 (s, 4H), 4.95 (s, 4H), 4.2 (s, 4H), 3.3 (t, $J=7$ Hz, 4H), 3.2 (t, $J=7$ Hz, 4H) 1.8 (quint, $J=7$ Hz, 4H).

Mass Spectrum: calcd mass for $\text{C}_{22}\text{H}_{20}\text{N}_6\text{O}_6$, 604.7062, found $[\text{M}+1]=605.9$, $[\text{M}+2]/2=303.4$.

Example 20

N,N'-Bis(N-(4-aminomethylbenzyl)butyramido)- N,N'-bis(methyl)terephthalamide

To a solution of mono-Boc protected p-xylylene diamine (248 mg, 1.05 mmol, 1 equiv) in dichloromethane (20 mL) was added N-Cbz-N-methyl-4-aminobutyric acid (287 mg, 1.14 mmol, 1.1 equiv, prepared in a manner similar to that of N-Cbz-4-amino butyric acid). The mixture was cooled to 0°C. HOBT (171 mg, 1.27 mmol, 1.2 equiv) and EDC (243 mg, 1.2 mmol, 1.2 equiv) were added. NMM (30 drops) was added to adjust pH to >7. The solution was stirred at 0°C for 1 h and at r.t. overnight. Dichloromethane was added, and the solution was washed with 0.1 N HCl, saturated sodium bicarbonate, and brine. The organic layer was dried over MgSO_4 , filtered, and concentrated in vacuo. Ethanol (25 mL) and palladium (94 mg, 10%/C) were added to the residue and the mixture was stirred under hydrogen (1 atm) for 2.5 h. The mixture was filtered, and the ethanol was removed in vacuo.

To the residue (315 mg, 0.94 mmol, 2.4 equiv) was added dichloromethane (10 mL). Triethylamine (0.144 mL, 105 mg, 1.03 mmol, 2.6 equiv) and terephthaloyl dichloride (81 mg, 0.4 mmol, 1 equiv) were added and the solution was stirred over three days. The solution was washed with 0.05 N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over MgSO_4 , filtered, and concentrated in vacuo. TFA and dichloromethane (10 mL each) were added and the solution was stirred for 1 h. The solution was

concentrated over vacuum and rinsed twice with ether. The crude product was purified on the Waters LC (2-30% gradient) to yield 30 mg of 90% pure bis HCl salt of the title compound.

Analysis. ¹H NMR (D₂O) δ 7.4-7.2 (m, 12H), 4.4 (d, J=5 Hz, 2H), 4.2 (d, J=2 Hz, 2H), 4.1 (s, 4H), 3.5 (m, 2H), 3.2 (m, 2H), 3.0 (d, J=5 Hz, 3H), 2.9 (d, J=14 Hz, 3H), 2.4 (m, 2H), 2.1 (m, 2H), 1.9 (m, 2H), 1.8 (m, 2H). Mass Spectrum: calcd mass for C₂₄H₄₄N₆O₄, 600.7612, found [M+1]=601.9, [M+2]/2=301.6.

Example 21

--N,N'-Bis(N-(4-aminomethylbenzamido)-N-methyl-4-aminobutyl)-p-xylylene diamide

Benzyl chloroformate (1.570 mL, 1877 mg, 11 mmol, 1.1 equiv) and 4-(N-methyl) aminobutyric acid (1530 mg, 10 mmol, 1 equiv) were added to a solution of triethylamine (3.832 mL, 2.78 mg, 27.5 mmol, 2.75 equiv) in THF-water (50 mL each). The solution was stirred overnight. Aqueous HCl, 1.5 N, was added until a pH of about 1 was reached. The product was extracted with dichloromethane. The organic layer was concentrated in vacuo, dissolved in dichloromethane, and washed with 1.5 N HCl. The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo.

To a solution of p-xylylene diamine (185 mg, 1.36 mmol, 1.0 equiv) in dichloromethane (30 mL) was added N-Cbz-N-methyl-4-aminobutyric acid (751 mg, 3.0 mmol, 2.2 equiv). The mixture was cooled to 0°C. HOBT (417 mg, 3.1 mmol, 2.3 equiv) and EDC (576 mg, 3.0 mmol, 2.2 equiv) were added. NMM (30 drops) was added to adjust pH to >7. DMF (1 mL) was added. The solution was stirred at 0°C for 30 min and at r.t. overnight. Dichloromethane (50 mL) was added, and the solution was washed with 0.1 N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo. Ethanol (25 mL) and palladium (94 mg, 10%/C) were added to the residue and the mixture was stirred under hydrogen (1 atm) for 2.5 h. The mixture was filtered, and the ethanol was removed in vacuo. Hydrogenation was repeated overnight with 700 mg palladium.

To a solution of the residue (257 mg, 0.77 mmol, 1.0 equiv) in dichloromethane (20 mL) was added Boc-p-aminomethyl benzoic acid (445 mg, 1.77 mmol, 2.3 equiv). The mixture was cooled to 0°C. HOBT (239 mg, 1.77 mmol, 2.3 equiv) and EDC (340 mg, 1.77 mmol, 2.3 equiv) were added. NMM (30 drops) was added to adjust pH to >7. DMF (2 mL) was added. The solution was stirred at 0°C for 0.5 h and at 50°C overnight. Dichloromethane (50 mL) was added, and the solution was washed with 0.1 N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over MgSO₄, filtered, and concentrated in vacuo. TFA and dichloromethane (10 mL each) were added and the solution was stirred for 1.5 h. The solution was concentrated under vacuum and rinsed twice with ether. The crude product was purified on the Waters LC (2-30% gradient) to yield >95% pure bis-HCl salt of the title compound.

Analysis. ¹H NMR (D₂O) δ 7.5-7.1 (m, 12H), 4.4-4.1 (m, 6.4H), 3.5 (m, 1.4H), 3.2 (m, 2.1H), 3.0 (s, 3.5H), 2.9 (s, 2.8H), 2.4 (m, 2.1H), 2.1 (m, 2.1H), 1.9 (m, 2.1H), 1.8 (m, 2.1H). Mass Spectrum: calcd mass for C₃₄H₄₄N₆O₄, 600.7612, found [M+1]=601.5, [M+2]/2=301.5.

Example 22

N,N'-Bis(trans-4-aminomethylcyclohexyl-1-amido-propylene)-1,4-benzenedimethanol dicarbamate

Diaminopropane (3.332 mL, 2.959 g, 40 mmol, 6.9 equiv) was dissolved in basic alumina-filtered dioxane (40 mL). Boc anhydride (1272 mg, 5.8 mmol, 1 equiv) in dioxane (60 mL) was added dropwise. The solution was stirred for 3 days. The solution was concentrated in vacuo. The residue was dissolved in water and filtered. The aqueous layer was extracted three times with dichloromethane. The combined organic layers were dried over MgSO₄, filtered, and concentrated in vacuo to yield an oil.

The mono-Boc diaminopropane (248 mg, 1.4 mmol, 2.3 equiv) was dissolved in dichloromethane (12 mL). Triethylamine (0.220 mL, 160 mg, 1.6 mmol, 2.6 equiv) and previously-synthesized 1,4-benzyl dichloroformate (0.112 mL,

164 mg, 0.62 mmol, 1 equiv) were added. The solution was stirred overnight. The solution was washed with 0.1 N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over MgSO_4 , filtered, and concentrated *in vacuo* to yield a white powder. The powder was dissolved in 10 mL each of TFA and dichloromethane and stirred for 45 min. The solution was concentrated *in vacuo* and the residue was rinsed twice with ether.

To a solution of *trans*-4-(aminomethyl)cyclohexane-carboxylic acid (694 mg, 4.4 mmol, 1.0 equiv) in THF (40 mL) was added Boc anhydride (1115 mg, 5.1 mmol, 1.2 equiv). The solution was stirred for three days. Dichloromethane was added and the solution was washed with 0.1 N HCl and brine. The organic layer was dried over MgSO_4 , filtered, and concentrated *in vacuo*.

To a solution of Boc-*trans*-4-(aminomethyl)cyclohexane carboxylic acid (545 mg, 2.1 mmol, 1 equiv) in dichloromethane (25 mL) at 0°C was added diaminopropane benzenedimethanol dicarbamate (106 mg, 0.3 mmol, .15 equiv), EDC (395 mg, 2.05 mmol, 0.98 equiv), and HOBT (270 mg, 2 mmol, 0.95 equiv). NMM (30 drops) and DMF (2 mL) were added. The solution was stirred at 0°C for 1 hour and at room temperature (r.t.) overnight. The solution was washed with 0.1N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried over MgSO_4 , filtered, and concentrated *in vacuo*. TFA and dichloromethane (10 mL each) were added and the solution was stirred for 1 h. The solution was concentrated under vacuum and rinsed twice with ether. The crude product was purified on the Waters LC (2-30% gradient) to yield 3 mg of 92% pure bis-HCl salt of the title compound.

Analysis. ^1H NMR (D_2O) δ 7.4 (s, 4H), 5.1 (d, $J=18.5$ Hz, 3.6H), 3.1 (m, 4.4H), 2.8 (d, $J=8$ Hz, 4.4H), 2.4-2.2 (m, 1.8H), 2.0 (m, 1.8H), 1.8 (m, 6.2H), 1.6 (m, 4.4H), 1.4 (m, 4.4H), 1.0 (m, 4.4H). Mass Spectrum: calcd mass for $\text{C}_{22}\text{H}_{32}\text{N}_6\text{O}_6$, 616.8015, found $[M+1]=617.8$, $[M+2]/2=309.7$.

Example 23

N,N'-(Bis(methyl)-bis(*N*-(4-aminomethyl-
benzyl)succinamido)-*p*-xylylene diamide

Sodium hydride (0.22 g, 7.45 mmol, 5.0 equiv) was added to a solution of *N,N'*-bis(Boc)xylylenediamine (0.50 g, 1.49 mmol, 1.0 equiv) in *N,N*-dimethylformamide (20 mL) containing 4Å sieves at 0°C. Gas evolution was observed. The reaction mixture was stirred at 0°C for 0.5 h. Iodomethane (0.93 mL, 14.9 mmol, 10 equiv) was added to the reaction mixture, and the resulting grey suspension was stirred at 23°C for 0.5 h and at 60°C for 6.5 h. The reaction mixture was carefully quenched with saturated aqueous sodium bicarbonate at 0°C, then partitioned between dichloromethane and water (3 x 200 mL). The organic layer was dried over sodium sulfate and concentrated to yield crude *N,N'*-bis(Boc)-bis(methyl)-xylylenediamine as a yellow oil.

Representative Procedure I: A solution of this crude *N,N'*-bis(Boc)-bis(methyl)xylylenediamine in 50% trifluoroacetic acid in dichloromethane (10 mL) was stirred at 23°C for 0.5 h. The brown solution was concentrated. Diethyl ether was added to the residue, and the mixture was concentrated. The residue obtained was washed with diethyl ether (two portions), providing the *N,N'*-bis(methyl)-xylylene diamine bis(trifluoroacetate) as a yellow solid.

Representative Procedure II:

1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.16 g, 0.86 mmol, 3.3 equiv) was added to a mixture of 1-hydroxybenzotriazole hydrate (0.11 g, 0.86 mmol, 3.3 equiv), *N,N'*-bis(methyl)xylylene diamine bis(trifluoroacetate) (0.10 g, 0.26 mmol, 1.0 equiv), *N*-(4-*N*-Boc-aminomethylbenzyl)-amidossuccinic acid (0.26 g, 0.78 mmol, 3.0 equiv), and 4-methylmorpholine (0.20 mL, 1.82 mmol, 7.0 equiv) at 0°C. The pH of the reaction mixture was found to be 8. The yellow suspension was stirred at 0°C for 1 h and at 23°C for 20 h. The reaction mixture was partitioned between dichloromethane, 0.05 N hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate and concentrated

to give crude *N,N'*-(bis(methyl)-bis(*N*-(4-*N*-Boc-aminomethylbenzyl)succinamido)-*p*-xylylene diamide as a brown residue.

As in Representative Proc dur I, a solution of the crude *N,N'*-(bis(methyl)-bis(*N*-(4-*N*-Boc-aminomethylbenzyl)succinamido)-*p*-xylylene diamide in 50% trifluoroacetic acid in dichloromethane (8 mL) was stirred at 23°C for 0.5 h, and then concentrated. Diethyl ether was added to the residue, and the mixture was concentrated. The solid obtained was washed with diethyl ether and purified by preparative liquid chromatography, providing *N,N'*-(bis(methyl)-bis(*N*-(4-aminomethylbenzyl)succinamido)-*p*-xylylene diamide bis(trifluoroacetate).

Analysis. ¹H NMR (CD₃OD): 7.40 (s, 8 H); 7.243 (s), 7.241 (s), 7.26 (s), (4 H total); 4.68 (d), 4.58 (d), (4 H total); 4.41 (s, 4 H); 4.10 (s, 4 H); 3.01 (d), 2.90 (d), (6 H total); 2.77 (t, 4 H); 2.58 (t, 4 H). Mass Spectrum: calcd for C₃₄H₄₆N₆O₄ (M(H⁺)₂): 602; found: 602

Example 24

N,N'-Bis(*N*-(4-aminomethylcyclohexylmethyl)-glutaramido)-*p*-xylylene diamide

Representative Procedure III: A mixture of *N,N'*-bis(glutaryl)-*p*-xylylenediamide dimethyl ester (0.108 g, 0.25 mmol, 1.0 equiv) in 1,4-cyclohexane-bis(methylamine) (1 mL) was stirred at 70°C for 18 h. The reaction mixture was diluted with water and subjected to centrifugation. The liquid was decanted to give a residue. A mixture of this residue in water was centrifuged, and the liquid decanted. The resulting residue was dried under vacuum over Drierite and purified by preparative liquid chromatography, providing *N,N'*-bis(*N*-(4-aminomethylcyclohexylmethyl)glutaramido)-*p*-xylylene diamide bis(trifluoroacetate).

Analysis. ¹H NMR (CD₃OD): 7.23 (s, 4 H), 4.33 (s, 4 H), 3.03 (d, 4 H), 2.78 (d, 4 H), 2.22 (m, 8 H), 1.83 (m, 12 H), 1.51 (m, 4 H), 0.98 (m, 8 H). Mass Spectrum: calcd for C₃₄H₅₈N₆O₄ (M(H⁺)₂): 614; found: 614.

Exempl 25

N,N'-Bis(methyl)-bis(*N*-(4-aminomethylcyclohexyl-methyl)succinamido)-*p*-xylylene diamide

A solution of di-*tert*-butyl dicarbonate (5.0 g, 0.023 mol, 1.0 equiv) in tetrahydrofuran (100 mL) was added dropwise over 4 h to a mixture of 1,4-cyclohexane-bis(methylamine) (30 mL, 0.18 mol, 8.0 equiv) in tetrahydrofuran (150 mL). The resulting white suspension was stirred at 23°C for 24 h, then partitioned between dichloromethane, water (three portions), and saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate and concentrated to give crude *N*-mono(Boc)-1,4-cyclohexane-bis(methylamine) as a yellow solid.

Representative Procedure IV:

3-Carbomethoxypropionyl chloride (0.17 mL, 1.38 mmol, 1.0 equiv) was added to a biphasic mixture of *N*-mono(Boc)-1,4-cyclohexane-bis(methylamine) (0.5 g, 2.07 mmol, 1.5 equiv) in dichloromethane (5 mL) and saturated aqueous sodium bicarbonate (5 mL). The reaction mixture was stirred at 23°C for 23 h, then partitioned between dichloromethane, saturated aqueous sodium bicarbonate, 0.05 N hydrochloric acid, and saturated aqueous sodium chloride. The organic layer was dried over sodium sulfate and concentrated, providing crude *N*-(4-*N*-Boc-aminomethylcyclohexylmethyl)amidomethylsuccinate (463 mg) as a white solid.

Representative Procedure V: A solution of barium hydroxide octahydrate (0.51 g, 1.63 mmol, 1.25 equiv) in methanol (15 mL) was added to *N*-(4-*N*-Boc-aminomethylcyclohexylmethyl)amidomethylsuccinate (463 mg, 1.30 mmol, 1.0 equiv). The reaction mixture was stirred at 23°C for 17 h, then it was acidified with 1 N hydrochloric acid. The mixture was partitioned between dichloromethane (three portions) and water. The combined organic layers were dried over sodium sulfate and concentrated, yielding *N*-(4-*N*-Boc-aminomethylcyclohexylmethyl)amidomethylsuccinic acid as a white solid.

N,N'-Bis(methyl)-xylylene diamine bis(trifluoroacetate) (0.100 g, 0.26 mmol, 1.0 equiv) and *N*-(4-*N*-Boc-

aminomethylcyclohexylmethyl)amidosuccinic acid were coupled in the presence of 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate, as in Representative Procedure II. The product obtained was subsequently deprotected to give *N,N'*-bis(methyl)-bis(*N*-(4-aminomethylcyclohexyl)succinamido)-*p*-xylylene diamide bis(trifluoroacetate) in the presence of 50% trifluoroacetic acid in dichloromethane, as in Representative Procedure I, followed by purification via preparative liquid chromatography.

Analysis. ^1H NMR (CD_3OD): 7.21 (s), 7.27 (s), 7.23 (s), 7.12 (s), (4 H total); 4.61 (d), 4.55 (d), (4 H total); 3.20 (m, 4 H); 2.97 (d), 2.86 (d), (6 H total); 2.72 (m, 8); 2.52 (m, 4 H); 1.81 (m, 8 H); 1.50 (m, 4 H); 0.98 (m, 8 H). Mass Spectrum: calcd for $\text{C}_{34}\text{H}_{58}\text{N}_6\text{O}_4$ ($\text{M}(\text{H}^+)_2$): 614; found: 614.

Example 26

N,N'-Bis(*N*-(4-aminomethylcyclohexylmethyl)-succinamido)-*p*-xylylene diamide

N,N'-Bis(*N*-(4-aminomethylcyclohexylmethyl)-succinamido)-*p*-xylylene diamide bis(trifluoroacetate) was prepared from *N,N'*-bis(succinyl)-*p*-xylylenediamide dimethyl ester in a manner analogous to Representative Procedure III.

Analysis. ^1H NMR (CD_3OD): 8.40 (s, 2 H), 7.99 (s, 2 H), 7.22 (m, 4 H), 4.33 (s, 4 H), 3.02 (s, 4 H), 2.76 (s, 4 H), 2.50 (m, 8 H), 1.83 (s, 8 H), 1.45 (m, 4 H), 0.98 (m, 8 H). Mass Spectrum: calcd for $\text{C}_{32}\text{H}_{54}\text{N}_6\text{O}_4$ ($\text{M}(\text{H}^+)_2$): 586; found: 586.

Example 27

N,N'-Bis(methyl)-bis(*N*-(4-aminomethylcyclohexylmethyl)-glutaramido)-*p*-xylylene diamine

N,N'-Bis(methyl)-bis(*N*-(4-aminomethylcyclohexylmethyl)glutaramido)-*p*-xylylene diamine bis(trifluoroacetate) was prepared from methyl 4-(chloroformyl)butyrate substituted for 3-carbomethoxypropionyl chloride according to an experimental procedure analogous to that of Example 25.

Analysis. ^1H NMR (CD_3OD): 8.01 (br, 2 H), 7.12 (m, 4 H), 4.57 (m, 4 H), 3.00 (m, 4 H), 2.95 (d, 4 H), 2.88 (s, 2 H), 2.75 (d, 4 H), 2.26 (m, 4 H), 1.84 (m, 12 H), 1.50 (m, 4 H), 0.96 (m, 8 H). Mass Spectrum: calcd for $\text{C}_{36}\text{H}_{62}\text{N}_6\text{O}_4$ ($\text{M}(\text{H}^+)_2$): 642; found: 642.

Example 28

N,N'-Bis(*N*-(4-aminomethylbenzyl)-dimethyl-2,3-isopropylidenetartaramido)-*p*-xylylene diamide

A mixture of *p*-xylylenediamine (0.15 g, 1.10 mmol, 1.0 equiv) and (4*R*,5*R*)-(-)-dimethyl 2,3-*O*-isopropylidene-*L*-tartrate (2.0 mL, 11.0 mmol, 10 equiv) was stirred at 90°C for 16 h. The mixture was triturated with 50% hexanes in diethyl ether and diethyl ether (two portions). The residue obtained was partitioned between dichloromethane and water. The organic layer was dried over sodium sulfate and concentrated to give crude *N,N'*-bis-(dimethyl-2,3-isopropylidene)-*p*-xylylenediamide dimethyl ester as a brown residue.

A mixture of the crude *N,N'*-bis(dimethyl-2,3-isopropylidene)-*p*-xylylenediamide dimethyl ester and *p*-xylylenediamine (1.5 g) was stirred at 90°C for 17 h. The reaction mixture was partitioned between dichloromethane and water (three portions). The organic layer was dried over sodium sulfate and concentrated. The resulting residue was purified by preparative liquid chromatography, providing *N,N'*-bis(*N*-(4-aminomethylbenzyl)-dimethyl-2,3-isopropylidene-tartaramido)-*p*-xylylene diamide bis(trifluoroacetate).

Analysis. ^1H NMR (CD_3OD): 7.38 (s, 8 H), 7.25 (s, 4 H), 4.61 (s, 4 H), 4.42 (m, 8 H), 4.01 (s, 4 H), 1.42 (s, 12 H). Mass Spectrum: calcd for $\text{C}_{38}\text{H}_{50}\text{N}_6\text{O}_4$ ($\text{M}(\text{H}^+)_2$): 718; found 718.

Example 29

N,N'-Bis(*N*-(3-aminomethylcyclohexylmethyl)-succinamido)-*p*-xylylene diamide

N,N'-Bis(*N*-(3-aminomethylcyclohexylmethyl)-succinamido)-*p*-xylylene diamide bis(trifluoroacetate) was prepared from 1,3-cyclohexane-bis(methylamine) according to an

experimental procedure analogous to that of Representative
Procedure III.

Analysis. ^1H NMR (CD_3OD): 8.40 (br, 2 H), 7.97 (br, 2 H), 7.24 (s, 4 H), 4.34 (m, 4 H), 3.02 (m, 4 H), 2.71 (m, 4 H), 2.50 (m, 8 H), 1.78 (m, 6H), 1.50 (m, 6H), 1.26 (m, 2 H), 0.85 (m, 4 H), 0.66 (m, 2H). Mass Spectrum: calcd for $\text{C}_{32}\text{H}_{54}\text{N}_6\text{O}_4$ ($\text{M}(\text{H}^+)_2$): 586; found 586.

Example 30

N,N'-Bis(*N*-methyl-*N*-(4-aminomethylbenzyl)- succinamido)-*p*-xylylene diamide

Lithium aluminum hydride (1.8 g, 44.5 mmol, 3.5 equiv) was added portionwise to a solution of *N*-mono(Boc)-*p*-xylylenediamine in tetrahydrofuran (100 mL) at 0°C. Gas evolution was observed. The grey suspension was stirred at 23°C for 2 h, by which time gas evolution had ceased. The reaction mixture was refluxed for 16 h, then carefully quenched at 0°C by the dropwise addition of water (1.8 mL). Gas evolution was seen. 15% Aqueous sodium hydroxide (1.8 mL) and water (5.4 mL) was added dropwise to the suspension at 23°C. The mixture was stirred at 23°C for 0.5 h, then filtered. The filter cake was washed with tetrahydrofuran and dichloromethane. The filtrate was concentrated, providing crude *N*-mono(methyl)-*p*-xylylenediamine (0.68 g) as a yellow oil.

A solution of *N*-mono(methyl)-*p*-xylylenediamine (0.10 g, 0.67 mmol, 1.0 equiv) and benzophenone imine (0.11 mL, 0.67 mmol, 1.0 equiv) in dichloromethane (5 mL) was stirred with 4Å sieves at 23°C for 3 d. The reaction mixture was filtered through celite, and the filtrate was concentrated to give crude *N*-mono(methyl)-*p*-xylylenediamine benzophenone imine (190 mg) as a yellow oil.

4-Methylmorpholine (2.0 mL, 18.4 mmol, 2.5 equiv) was added to a mixture of *p*-xylylenediamine (1.0 g, 7.34 mmol, 1.0 equiv) and succinic anhydride (1.32 g, 13.2 mmol, 1.8 equiv) in *N,N*-dimethylformamide (25 mL). The reaction mixture was stirred at 50°C for 22 h. After the mixture was acidified with 1 N hydrochloric acid, it was extracted with

dichloromethane (three portions). The aqueous layer was filtered. The solid obtained was washed with water and diethyl ether, yielding crude *N,N'*-bis(succinyl)-*p*-xylylenediamide diacid (1.83 g) as an off-white solid.

N-Mono(methyl)-*p*-xylylenediamine benzophenone imine and *N,N'*-bis(succinyl)-*p*-xylylenediamide diacid were coupled in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate as in Representative Procedure II to give *N,N'*-bis(*N*-methyl-*N*-(4-aminomethylbenzyl)succinamido)-*p*-xylylenediamide di(benzophenone imine).

Representative Procedure VI: Hydroxylamine
hydrochloride (20 mg, 0.27 mmol, 5.0 equiv) was added to a solution of *N,N'*-bis(*N*-methyl-*N*-(4-aminomethylbenzyl)-succinamido)-*p*-xylylene diamide di(benzophenone imine) (49 mg, 0.053 mmol, 1.0 equiv) in tetrahydrofuran (1.0 mL). The yellow solution was stirred at 23°C for 2.5 h, then concentrated. The residue obtained was washed with diethyl ether (three portions), then purified by preparative liquid chromatography. *N,N'*-Bis(*N*-methyl-*N*-(4-aminomethylbenzyl)succinamido)-*p*-xylylene diamide bis(trifluoroacetate) was obtained.

Analysis. ^1H NMR (D_2O): 7.28 (m, 12 H), 4.50 (m, 4 H), 4.30 (m, 4 H), 4.10 (s, 4 H), 2.95 (s, 4 H), 2.85 (m, 2 H), 2.60 (m, 8 H). MS: $\text{C}_{43}\text{H}_{46}\text{N}_6\text{O}_4$ ($\text{M}(\text{H}^+)$): 602; found 602.

Example 31

Bis(1,4-cyclohexyldimethylamineglycine)-
1,4-benzenedimethanol dicarbamate

1,4-Benzenedimethanol dichloroformate and glycine methyl ester were coupled in the presence of dichloromethane and saturated aqueous sodium bicarbonate as in Representative Procedure IV, providing glycine-1,4-benzenedimethanol dicarbamate dimethyl ester. Following Representative Procedure V, glycine-1,4-benzenedimethanol dicarbamate dimethyl ester was hydrolyzed with barium hydroxide octahydrate to glycine-1,4-benzenedimethanol dicarbamate diacid. *N*-Mono(Boc)-1,4-cyclohexane-bis(methylamine) and glycine-1,4-benzenedimethanol diacid were coupled in the

presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate, as in Representative Procedure II. The product was deprotected in 50% trifluoroacetic acid in dichloromethane according to Representative Procedure I. Following preparative liquid chromatography, bis(1,4-cyclohexyldimethylamineglycine)-1,4-benzenedimethanol dicarbamate bis(trifluoroacetate) was obtained.

Analys. ^1H NMR (CD_3OD): 8.00 (br, 2 H), 7.34 (s, 4 H), 5.08 (s, 4 H), 3.72 (s, 4 H), 3.02 (t, 4 H), 2.76 (d, 4 H), 1.80 (d, 8 H), 1.50 (m, 4 H), 1.00 (m, 8 H). Mass Spectrum: calcd for $\text{C}_{30}\text{H}_{50}\text{N}_6\text{O}_6$ ($\text{M}(\text{H}^+)_2$): 590; found: 590.

Example 32

Bis(1,4-cyclohexyldimethylamine-N-methyl-N-glycine)-1,4-benzenedimethanol dicarbamate

Glycine-1,4-benzenedimethanol dicarbamate diacid and N-mono(methyl)-p-xylylenediamine benzophenone imine were coupled as in Representative Procedure II in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 1-hydroxybenzotriazole hydrate to give bis(1,4-cyclohexyldimethylamine-N-methyl-N-glycine)-1,4-benzenedimethanol dicarbamate di(benzophenone imine). As in Representative Procedure VI, the di-imine was hydrolyzed in the presence of hydroxylamine hydrochloride.

Bis(1,4-cyclohexyldimethylamine-N-methyl-N-glycine)-1,4-benzenedimethanol dicarbamate bis(hydrochloride) was obtained after preparative liquid chromatography.

Analysis. ^1H NMR (CD_3OD): 7.35 (m, 12 H), 5.10 (m, 4 H), 4.60 (s, 4 H), 4.05 (d, 8 H), 2.92 (d, 6 H). Mass Spectrum: calcd for $\text{C}_{32}\text{H}_{41}\text{N}_6\text{O}_6$ (MH^+): 605; found: 605.

Example 33

N,N'-Bis(trans-4-aminomethyl-cyclohexyl-1-amidobutyl)-1,4-benzene dimethanol dicarbamate

Diaminobutane (2.11 g, 24 mmol, 7.3 equiv) was dissolved in basic alumina-filtered dioxane (75 mL). A

solution of Boc anhydride (720 mg, 3.3 mmol, 1 equiv) in dioxane (75 mL) was added dropwise. The reaction mixture was stirred overnight and then concentrated *in vacuo*. Water was added to the residue. The suspension obtained was filtered. The filtrate was extracted three times with dichloromethane. The combined organic layers were dried over MgSO_4 , filtered, and concentrated *in vacuo* to yield an oil.

The N-mono(Boc) diaminobutane (551 mg, 2.9 mmol, 2.2 equiv) was dissolved in dichloromethane (20 mL). Triethylamine (0.420 mL, 3.0 mmol, 2.3 equiv) and previously synthesized 1,4-benzyl dichloroformate (334 mg, 1.3 mmol, 1 equiv) were added. The solution was stirred for 6 h. Dichloromethane (50 mL) was added, and then 0.1N HCl. The product was removed by filtration. The product was dissolved in 10 mL each of TFA and dichloromethane. The solution was stirred for 30 min and concentrated *in vacuo*.

To a solution of *trans*-4-(aminomethyl)cyclohexanecarboxylic acid (5.03 g, 32 mmol, 1.0 equiv) in dioxane-water (160 mL each) was added K_2CO_3 (9.75 g) and Boc anhydride (7.65 g, 35 mmol, 1.1 equiv). The solution was stirred for 6 h. The solution was acidified to pH 3 with 1.5N HCl. The solution was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were dried over MgSO_4 , filtered, and concentrated *in vacuo*.

To a solution of Boc-*trans*-4-(aminomethyl)cyclohexanecarboxylic acid (418 mg, 1.6 mmol, 1 equiv) in dichloromethane (40 mL) at 0°C was added diaminobutane benzene dimethanol dicarbamate (<0.73 mmol), EDC (311 mg, 1.6 mmol, >2 equiv), and HOBT (218 mg, 1.6 mmol, >2 equiv). NMM (5 mL) and DMF (2 mL) were added. The solution was stirred at 0°C for ~1 hour and at r.t. overnight. The solution was washed with .1N HCl, saturated aqueous sodium bicarbonate, and brine. The organic layer was concentrated *in vacuo*. TFA and dichloromethane (10 mL each) were added and the solution was stirred for ~1 h. The solution was concentrated under vacuum and the resulting residue rinsed twice with ether. The crude product was purified on the Waters LC (2-30% gradient) to yield ~30 mg of 98% pure bis(HCl) salt of the title compound.

Analysis. ^1H NMR (D_2O) δ 7.4 (s, 4H), 5.0 (s, 4H), 3.1 (m, 8H), 2.8 (d, $J=7$ Hz, 4H), 2.1 (m, 2H), 1.8 (d, $J=9$ Hz, 8H), 1.6 (m, 2H), 1.4 (br, 12H), 1.0 (m, 4H). Mass Spectrum: calcd mass for $\text{C}_{34}\text{H}_{36}\text{N}_6\text{O}_6$, 644.8552, found $[\text{M}+1]=645.7$, $[\text{M}+2]/2=323.4$.

Example 34

N,N'-Bis[4-(aminomethylbenzamido)butyl]-terephthalyldiamide

A solution of di-tert-butyl dicarbonate (1.2 g, 5.8 mmol) in THF (15 mL) was added dropwise to a solution of diaminobutane (2.9 g, 33 mmol) in THF (35 mL). The mixture was stirred overnight and concentrated in vacuo. Water was added. The suspension was filtered. The filtrate was washed with dichloromethane (3 x 25 mL). The combined organic layers were washed with water. The organic layer was dried over MgSO_4 , filtered, and concentrated in vacuo to yield an oil.

The mono(Boc)-diaminobutane (463 mg, 2.5 mmol) was added to a mixture of terephthalic acid (187 mg, 1.1 mmol), EDC (478 mg, 2.5 mmol), HOBT (345 mg, 2.6 mmol), and NMM (50 drops) in DMF (20 mL). The solution was stirred overnight. The reaction mixture was partitioned between EtOAc, 0.1N HCl, 0.2N NaOH, and brine. The organic layer was concentrated in vacuo. The residue was dissolved in 10 mL each of dichloromethane and TFA. The reaction mixture was stirred for 3 h. The solution was concentrated in vacuo. The residue was rinsed twice with ether. Aqueous NaOH (1N) was added, and the solution was extracted with dichloromethane. The aqueous layer was concentrated in vacuo to yield aminobutylterephthalyldiamide.

A solution of di-tert-butyl dicarbonate (2.9 g, 13 mmol) in THF (30 mL) was added dropwise to p-aminomethyl benzoic acid (2 g, 13 mmol) in THF (30 mL). The mixture was stirred overnight and concentrated in vacuo. The Boc-protected p-aminomethyl benzoic acid (209 mg, 0.8 mmol) was combined with aminobutylterephthalyldiamide (180 mg, 0.6 mmol), EDC (167 mg, 0.9 mmol), HOBT (115 mg, 0.9 mmol), and NMM (30 drops) in DMF (10 mL). The solution was stirred for 3 days. The reaction mixture was partitioned between

EtOAc, 0.1 N HCl, water (three portions), and brine. A portion of the crude product was purified by flash chromatography to yield 25 mg. The purified compound was stirred in dichloromethane (8 mL) and TFA (8 mL) for 2h. The solution was concentrated *in vacuo*. The residue was rinsed twice with ether. The crude residue was dried over vacuum and purified by Prep LC on a 10-35% gradient of ACN in water (0.1% TFA) to yield 2 mg of >90% pure bis(TFA) salt of the title compound.

Analysis. ^1H NMR (D_2O) δ 7.85-7.80 (t, $J=7$ Hz, 7 H), 7.45 (d, $J=9$ Hz, 5H), 4.2 (s, 4H), 3.4 (s, 8H), 1.6 (s, 8H); calcd mass for $\text{C}_{32}\text{H}_{40}\text{N}_6\text{O}_4$ 572.3554, found $[\text{M}+1]=573.4$, $[\text{M}+2]/2=287.5$.

Example 35

N-(3-Aminomethylbenzylsuccinamido)-N'-(4-aminomethylbenzylsuccinamido)-p-xylylene diamide

To a solution of m-xylylene diamine (3.11 mL, 23.6 mmol) in dioxane (30 mL) was added dropwise a solution of di-tert-butyl dicarbonate (675 mg, 3.1 mmol) in dioxane (20 mL). The solution was stirred overnight, and the solvent was removed *in vacuo*. Water was added, and the suspension obtained filtered. The filtrate was extracted with ethyl acetate (3 x 20 mL). The combined organic layers were dried over MgSO_4 , filtered, and concentrated *in vacuo* to yield the mono-Boc protected meta-xylylene diamine. The same procedure was used to make the mono-Boc p-xylylene diamine.

To a solution of p-xylylene diamine (622 mg, 4.6 mmol) in dichloromethane (10 mL) was added succinic anhydride (1.01 g, 10.1 mmol). The mixture was stirred for 2 days. The solvent was removed *in vacuo*. The white residue (588 mg) was added to a mixture of N-mono(Boc)-m-xylylene diamine (150 mg, 0.64 mmol), HOBT (120 mg, .89 mmol), EDC (168 mg, .88 mmol), and NMM (50 drops) in DMF (5 mL) and dichloromethane (10 mL). The solution was stirred for 24 h. Dichloromethane (20 mL) was added, and the solution was washed with 0.2 N HCl and water. The organic layer was concentrated

in vacuo. Mass spectroscopy showed the presence of a compound with the desired mass.

The diacid (168 mg) was added to a mixture of N-mono(Boc)-p-xylylene diamine (80 mg, 0.34 mmol), HOBT (52 mg, 0.39 mmol), EDC (65 mg, 34 mmol), and NMM (30 drops) in DMF (5 mL). The solution was stirred overnight. The reaction mixture was partitioned between ethyl acetate, 0.1 N HCl, water (three portions), and brine. The organic layer was concentrated in vacuo. The product was dissolved in dichloromethane (5 mL) and TFA (5 mL). The solution was stirred for 1.5 h, then concentrated in vacuo. The residue was rinsed twice with ether. The crude residue was dried over vacuum and purified by Prep LC on a 2-27% gradient of ACN in water (0.1% TFA) to yield 3 mg of >98% pure bis(TFA) salt of the title compound.

Analysis. ^1H NMR (D_2O) δ 7.4-7.1 (m, 12H), 4.3-4.2 (m, 8H), 4.1 (s, 2H), 4.0 (s, 2H); calcd mass for $\text{C}_{32}\text{H}_{40}\text{N}_6\text{O}_4$ 572.3554, found $[\text{M}+1]=573.3$, $[\text{M}+2]/2=287.2$.

Example 36

N,N'-Bis(N-(4-Guanidylbenzylamine)-malonamido)-p-xylylene diamide

p-Xylylenediamine (4.1 g, 30.1 mmol) and triethylamine (12 mL, 86.1 mmol) were taken into dichloromethane (20 mL) and the resulting solution cooled to 0°C. Methyl malonyl chloride (6.4 mL, 60.0 mmol) in dichloromethane (10 mL) was added dropwise to the above solution and the mixture allowed to slowly warm to room temperature over one hour. Concentration in vacuo followed by addition of water (50 mL) and filtration afforded the crude diester. The diester is further purified by recrystallization from methanol/ether to give a colorless solid. ^1H -NMR (CDCl_3): 8.60 (br tr, 2H), 7.20 (s, 4H), 4.25 (d, 4H), 3.60 (s, 6H), 3.30 (s, 4H).

The diester (530 mg, 1.63 mmol) and 4-aminobenzylamine (3.2 mL, 28.6 mmol) were heated neat at 45°C with stirring over twelve hours to give a yellow solid. The crude mixture was taken up into boiling methanol (50 mL)

and the resulting suspension allowed to cool to room temperature. Filtration followed by washing the solid with ether and drying in vacuo gives pure bisaniline as a colorless solid. $^1\text{H-NMR}$ (CDCl_3): 8.45 (tr, 2H), 8.25 (tr, 2H), 7.20 (s, 4H), 6.90 (d, 4H), 6.50 (d, 4H), 5.00 (s, 4H), 4.25 (d, 4H), 4.10 (d, 4H), 3.10 (s, 4H).

The bisaniline (20.0 mg, 0.04 mmol) and cyanamide (165 mg, 3.9 mmol) were heated neat at 50°C to form a homogeneous solution. Hydrogen chloride (4 M in dioxane, 50 μL , 0.2 mmol) was added and the mixture was allowed to stir at 50°C for one hour. Cooling to room temperature followed by addition of ether (25 mL) gave an insoluble yellow oil which was repeatedly washed with additional ether to remove traces of cyanamide. The crude oil was then taken into water (5 mL) and the desired product purified by preparative reverse phase HPLC to give the title compound bis-trifluoroacetate salt as a colorless solid.

Analysis. $^1\text{H-NMR}$ (DMSO-d_6): 9.75 (s, 2H), 8.55 (tr, 2H), 8.50 (tr, 2H), 7.40 (s, 8H), 7.30 (d, 4H), 7.20 (s, 4H), 7.15 (d, 4H), 4.25 (d, 4H), 4.21 (d, 4H), 3.15 (s, 4H).
Electrospray LRMS: Calculated for $\text{C}_{30}\text{H}_{36}\text{N}_{10}\text{O}_4$: $\text{MH}_2^{+2}/2$: 301.3
Found: $\text{MH}_2^{+2}/2$: 301.1.

Example 37

N,N'-Bis(N-(4-Guanidylbenzylamino)- succinamido-p-xylylene diamide

p-Xylylenediamine (4.6 g, 33.8 mmol) and triethylamine (13.5 mL, 96.9 mmol) were taken into dichloromethane (20 mL) and the resulting solution cooled to 0°C. Methyl succinyl chloride (8.3 mL, 67.6 mmol) in dichloromethane (10 mL) was added dropwise to the above solution and the mixture allowed to slowly warm to room temperature over one hour. Concentration in vacuo and addition of water (50 mL) followed by filtration and washing with warm water several times afforded the pure diester as a colorless solid. $^1\text{H-NMR}$ (CDCl_3): 8.35 (tr, 2H), 7.15 (s, 4H), 4.20 (d, 4H), 3.55 (s, 6H), 2.50 (tr, 4H), 2.40 (tr, 4H).

The di st r (580 mg, 1.79 mmol) and 4-aminobenzylamin (2.5 mL, 22 mmol) were heated neat at 45°C with stirring over twelve hours to giv a yellow solid. The crude mixture was taken up into boiling methanol (50 mL) and the resulting suspension allowed to cool to room temperature. Filtration followed by washing the solid with ether and drying *in vacuo* gives pure bisaniline as a colorless solid. ¹H-NMR (CDCl₃): 8.30 (tr, 2H), 8.10 (tr, 2H), 7.15 (s, 4H), 6.90 (d, 4H), 6.50 (d, 4H), 4.95 (s, 4H), 4.25 (d, 4H), 4.05 (d, 4H), 2.40 (s, 8H).

The bisaniline (91.0 mg, 0.17 mmol) and cyanamide (1.07 g, 25.5 mmol) were heated neat at 50°C to form a slurry. Hydrogen chloride (4 M in dioxane, 100 µL, 0.41 mmol) was added and the mixture was allowed to stir at 50°C for one hour. Cooling to room temperature followed by addition of ether (25 mL) gave an insoluble yellow solid which was repeatedly washed with additional ether to remove traces of cyanamide. The crude material was then taken into water (5 mL) and the desired product purified by preparative reverse phase HPLC to give the title compound bis-triflouroacetate salt as a colorless solid.

Analysis. ¹H-NMR (DMSO-d₆): 9.70 (s, 2H), 8.40 (tr, 2H), 8.35 (tr, 2H), 7.40 (s, 8H), 7.30 (d, 4H), 7.20 (s, 4H), 7.19 (d, 4H), 4.21 (d, 4H), 4.20 (d, 4H), 2.40 (s, 8H).
Electrospray LRMS: Calculated for C₃₂H₄₀N₁₀O₄: MH⁺: 629.7; MH₂^{+/2}: 315.4 Found: MH⁺: 629.6; MH₂^{+/2}: 315.3.

Example 38

N,N'-Bis(N-(4-Guanidylbenzylamino)- glutaramido-p-xylylene diamide

p-Xylylenediamine (3.9 g, 28.6 mmol) and triethylamine (12.0 mL, 85.8 mmol) were taken into dichloromethane (40 mL) and the resulting solution cooled to 0°C. Methyl glutaryl chloride (7.9 mL, 57.2 mmol) in dichloromethane (10 mL) was added dropwise to the above solution and the mixture allowed to slowly warm to room temperature over one hour. Concentration *in vacuo* and addition of water (50 mL) followed by filtration and washing

with warm water several times afforded the crude diester as a colorless solid which was employed without further purification. $^1\text{H-NMR}$ (CDCl_3): 8.40 (br tr, 2H), 7.20 (s, 4H), 4.25 (d, 4H), 3.60 (s, 6H), 2.30 (tr, 4H), 2.20 (tr, 4H), 1.85-1.75 (m, 4H).

The crude diester (800 mg, 2.04 mmol) and 4-aminobenzylamine (4.0 mL, 35.2 mmol) were heated neat at 80°C with stirring over twelve hours to give a yellow solid. The crude mixture was taken up into water (50 mL) to give a yellow suspension. Filtration followed by washing the solid with ethanol then ether and drying *in vacuo* gave the bisaniline as a tan solid. $^1\text{H-NMR}$ (CDCl_3): 8.30 (br tr, 2H), 8.10 (br tr, 2H), 7.20 (s, 4H), 6.95 (d, 4H), 6.55 (d, 4H), 4.95 (br s, 4H), 4.25 (d, 4H), 4.10 (d, 4H), 2.20 2.05 (m, 6H), 1.80-1.70 (m, 4H).

The bisaniline (150.0 mg, 0.26 mmol) and cyanamide (1.3 g, 30.9 mmol) were heated neat at 65°C to form a slurry. Hydrogen chloride (4 M in dioxane, 200 μL , 0.82 mmol) was added and the mixture was allowed to stir at 65°C for 30 minutes. Cooling to room temperature followed by addition of ether (25 mL) gave an insoluble yellow solid which was repeatedly washed with additional ether to remove traces of cyanamide. The crude material was then taken into water (5 mL) and the desired product purified by preparative reverse phase HPLC to give the title compound bis-trifluoroacetate salt as a colorless solid.

Analysis. $^1\text{H-NMR}$ ($\text{DMSO}-d_6$): 9.75 (s, 2H), 8.40 (tr, 2H), 8.30 (tr, 2H), 7.40 (s, 8H), 7.30 (d, 4H), 7.20 (s, 4H), 7.20 (d, 4H), 4.25 (d, 4H), 4.20 (d, 4H), 2.20-2.10 (m, 8H), 1.80-1.70 (m, 4H). Electrospray LRMS: Calculated for $\text{C}_{34}\text{H}_{44}\text{N}_{10}\text{O}_4$: MH^+ : 656.8; $\text{MH}_2^{+2}/2$: 329.4 Found: MH^+ : 657.7; $\text{MH}_2^{+2}/2$: 329.3

Other compounds prepared by methods analogous to those above include, but are not limited to, the following Examples:

Example No.	Compound
39	N,N'-Bis((N-(4-aminomethylbenzyl)succinamido))-p-phenethylenediamide
40	Bis((R,S)-2-(2-(4-guanidinobenzylamino)-2,3-dehydro-6-piperidone)-1,4-benzenedimethanol dicarbamate [isomer 1])
41	Bis((R,S)-2-(2-(4-guanidinobenzylamino)-2,3-dehydro-6-piperidone)-1,4-benzenedimethanol dicarbamate [isomer 2])
42	Bis((4-aminomethylanilido)glycine)-1,4-benzenedimethanol dicarbamate
43	Bis((4-guanidomethylanilido)glycine)-1,4-benzenedimethanol dicarbamate
44	Bis((3-aminomethylbenzylamido)glycine)-1,4-benzenedimethanol dicarbamate
45	Bis(trans-1,4-cyclohexyldimethylamine-glycine)-1,4-benzenedimethanol dicarbamate
46	4-(Guanidinobenzylamido)glycine-1,4-xylylene diurea
47	Bis(N-(4-aminomethylbenzyl)glycyl urea)-p-xylylene diamide
48	N,N-Bis((4-guanidobenzyluriedo)acetyl))-1,4-xylylene diamide
49	Bis-[4-N-(4-(aminomethyl)cyclohexylamido)-butyroyl))-1,4-xylylene diamide
50	Bis(N-(4-aminomethylbenzyl)glycyl urea)-1,4-phenethylenediamide
51	N,N'-Bis(methyl)-bis(glycine-trans-1,4-cyclohexylbis(methylamine)urea)-p-xylylene diamide
52	N,N'-Bis(methyl)-bis(glycine-p-xylylenediamine urea)-p-xylylene diamide
53	N,N'-Bis(methyl)-bis(4-aminomethylbenzoyl-trans-1,4-cyclohexylbis(methylamine)urea)xylylene diamide
54	N,N'-Bis(methyl)-bis(sarcosine-trans-1,4-cyclohexylbis(methylamine)urea)-p-xylylene diamide

VI. In Vitro Tryptase Inhibition Assay

The compounds to be assayed (approximately 1 mg) were dissolved in 200 μ L dimethylsulfoxide (DMSO) and diluted 1:10 into buffer containing 50 millimolar (mM) Tris-HCl (pH 8.2), 100 mM sodium chloride, and 0.05% polyoxyethylenesorbitan monolaurate (Tween-20[®], available from Sigma, St. Louis, Missouri). Seven additional threefold dilutions were made from the initial dilution into the same buffer supplemented with 10% DMSO. Aliquots (50 microliters, μ L) from each of the eight dilutions in the series were transferred to individual wells in a 96-well U-bottom microtiter plate. 25 μ L of a stock solution of tryptase (1.2 μ M, tryptase purified from HMC-1 cells, a human mast cell leukemia line provided by Dr. Joseph

Butterfield, see Butterfield et al. (1990) *J. Leukocyte Biol.* 47:409-419; also available commercially from ICN Biomedicals, Irvine, CA) was added to each well and the samples were mixed and incubated for one hour at room temperature. The tryptase solution was prepared by placing 60 $\mu\text{g/mL}$ of tryptase into solution with 10 mM MES (2-[N-Morpholino]ethane sulfonic acid) containing 2 mM CaCl_2 , 20% glycerol and 50 $\mu\text{g/mL}$ heparin. The enzyme reaction was initiated with the addition of the synthetic tripeptide substrate, tosyl-Gly-Pro-Lys-p-nitroanilide (available from Sigma, 25 μL ; 0.5 mM final concentration). The microtiter plates were immediately transferred to a UV/MAX Kinetic Microplate Reader (Molecular Devices) and hydrolysis of the chromogenic substrate was followed spectrophotometrically at 405 nanometers (nm) for five minutes. The enzyme assays routinely yielded linear progress curves under these conditions. Initial velocity measurements calculated from the progress curves by a kinetic analysis program (BatchKi; Petr Kuzmic, University of Wisconsin, Madison, WI) were used to determine apparent inhibition constants for each inhibitor.

Table II lists the inhibition constants (K_i , nanomolar (nM)) which were determined for several of the compounds of the present invention. According to the present invention, a compound was termed "active" or effective as a tryptase inhibitor when its K_i was less than 5000 nM.

Table II

Example #	K_i (nM)
1	0.56
2	20.00
3	9.00
4	4000.00
5	289.00
6	364.00

	7	227.00
	8	3.45
	9	150.00
	10	8.80
5	11	127.00
	12	86.00
	13	31.00
	14	366.00
	-- 15	11.00
10	16	396.00
	17	14.00
	18	5.00
	19	5.00
	20	107.00
15	21	1000.00
	22	918.00
	23	5.00
	24	55.00
	25	118.00
20	26	123.00
	27	138.00
	28	643.00
	29	1100.00
	30	2300.00
25	31	12.00
	32	874.00
	33	48.00

5

10

15

20

34	222.00
35	19.00
36	682.00
37	40.00
38	100.00
39	6.00
40	463.00
41	611.00
42	783.00
43	8100.00
44	55.00
45	10.00
46	10.00
47	62.00
48	700.00
49	366.00
50	43.00
51	130.00
52	79.00
53	1200.00
54	608.00

VII. In Vivo Testing

The allergic sheep model of asthma was employed for the *in vivo* evaluation of the compounds of the invention as antiasthmatics. These methods have been published previously (see Abraham et al. (1983) *Am. Rev. Respir. Dis.* 128:839-844; Allegra et al. (1983) *J. Appl. Physiol.* 55:726-730; Russi et al. (1985) *J. Appl. Physiol.* 59:1416-1422; Soler et al. ((1989) *J. Appl. Physiol.* 67:406-413. Each sheep serves as its own

control. Body weights for these animals ranged from 20-50 kilograms.

In these studies, 2 mg of Compound 2 of the invention was dissolved in buffered saline and the total solution delivered as an aerosol 0.5 hours before, 4 hours after, and 24 hours after antigen challenge (total dose = 27; n = 6). Compound 2 produced a statistically significant reduction in the early response and attenuated the late response to the antigen challenge as measured by Specific Lung Resistance (SRL). This is shown in Figure 1. The peak early response was taken as the average of the maximum values occurring immediately post-challenge. Peak late responses were calculated by averaging the maximum response values obtained for each animal within the 6-8 hour time period. This approach is conservative and eliminates the possible reduction in the late response due simply to averaging.

Compound 8 of Table II was administered as just described in a separate experiment. This compound also showed statistically significant early and late increases in SRL (Figure 2).

Twenty-four hours after antigen challenge in both the control and drug trial, the sheep developed airway hyperresponsiveness. Airway hyperresponsiveness is expressed as PC400, the concentration of carbachol that causes a 400% increase in SRL; therefore, a decrease in PC400 indicates hyperresponsiveness. Compounds 2 and 8 of Table II both were found to block the onset of hyperresponsiveness. As shown in Figure 3, Compound 2 maintained the PC400 at the baseline value of 24 ± 6 breath units ($p < 0.05$ vs. baseline). The number of breath units fell to 10 ± 4 for those animals in the control group. As shown in Figure 4, animals exposed to Compound 8 were found to have greater PC400 values compared to the baseline (15 ± 10 breath units vs. 12 ± 1 breath units in the control). Animals in the control group were found to have only about 5 ± 2 breath units after exposure to antigen challenge. Thus, treatment with either Compound 2 or Compound 8 of the invention resulted in a statistically significant improvement in airway function in antigen challenged sheep.

Compound 2 was also found to possess oral activity. Three doses of Compound 2 (40 mg in 60 mL water) were administered to sheep through an intergastric tube 1 hr before challenge, 4 hours post-challenge, and 24 hours post-challenge. As illustrated in Figure 5, animals treated with Compound 11 had an early phase SRL of about 270. Untreated animals showed an SRL of about 350. With respect to late phase reaction, animals treated with Compound 2 showed an SRL of about 70 as compared to an SRL of over 150 for untreated animals. Thus, Compound 2 showed significant anti-asthmatic properties when delivered orally.

Thus, the present invention provides compounds and compositions that are useful for the prevention and treatment of immunomediated inflammatory disorders, particularly those associated with the respiratory tract, including asthma, and the hyperresponsiveness phase associated with chronic asthma, in addition to allergic rhinitis. The present invention is also recognized as providing a method for treating immunomediated inflammatory disorders that are susceptible to treatment with a tryptase inhibitor of the present invention.

The disclosures in this application of all articles and references, including patents and patent applications, are incorporated herein by reference.

It is to be understood that the above description is intended to be illustrative and not restrictive. Many embodiments will be apparent to those of skill in the art upon reviewing the above description. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.


WHAT IS CLAIMED IS:

1. A compound effective to inhibit tryptase activity comprising the structure:

$Z-(X^1)_{n_1}-X^2-X^3-X^4-(X^5)_{n_5}-Y-(X'^5)_{n'_5}-X'^4-X'^3-X'^2-(X'^1)_{n'_1}-Z'$
and its pharmaceutically acceptable salts,
wherein:

Y is aryl or substituted aryl;

Z and Z' independently are



where T is $-\text{CH}_2\text{NH}_2$ or $-\text{NHC}(\text{NH})\text{NH}_2$; and p is an even integer between 4 and 10 inclusive;

X^1 , X'^1 , X^5 , and X'^5 are methylene or substituted methylene, and n_1 , n'_1 , n_5 and n'_5 independently are 0 or 1;
 X^2 , X'^2 , X^4 , and X'^4 are selected independently from

the group consisting of $-\text{NRC}(\text{O})-$, $-\text{NRC}(\text{O})\text{NR}'-$, $-\text{NRC}(\text{O})\text{O}-$, $-\text{C}(\text{O})\text{NR}-$ and $-\text{OC}(\text{O})\text{NR}-$, wherein R and R' are selected independently from the group consisting of hydrogen, lower alkyl, aryl, substituted lower alkyl, substituted aryl, aralkyl and substituted aralkyl; and

X^3 and X'^3 , are selected independently from the group consisting of cycloalkylene, cycloheteroalkylene, substituted cycloalkylene, substituted cycloheteroalkylene, lower alkylene and substituted lower alkylene.

2. The compound of claim 1, wherein Z is 4-aminomethylphenyl.

3. The compound of claim 2, wherein Z' is 4-aminomethylphenyl.

1 4. The compound of claim 2, wherein Z' is
2 4-aminomethylcyclohexyl.

1 5. The compound of claim 2, wherein Z' is
2 4-guanidylphenyl.

1 6. The compound of claim 2, wherein Z' is
2 4-guanidylcyclohexyl.

1 7. The compound of claim 2, wherein n_1 and n'_1 are
2 both 1, X^1 and X'^1 are both methylene, X^2 is $-NHC(O)-$ and X'^2 is
3 $-C(O)NH-$.

1 8. The compound of claim 7, wherein X^3 and X'^3 are
2 selected independently from the group consisting of methylene,
3 ethylene, and propylene.

1 9. The compound of claim 1, wherein Y is 1,3- or
2 1,4-phenylene or substituted phenylene.

1 10. The compound of claim 9, which is selected from
2 the group consisting of:

3 N,N'-bis(N-(4-aminomethylbenzyl)succinamido)-p-
4 xylylene diamide,

5 N,N'-bis(N-(4-aminomethylbenzyl)malonamido)-p-
6 xylylene diamide,

7 N,N'-bis(N-aminomethylbenzyl)glutaramido)-p-
8 xylylene diamide,

9 N,N'-bis(N-(3-aminomethylbenzyl)succinamido)-m-
10 xylylene diamide,

11 N,N'-(bis(methyl)-bis(N-(4-aminomethylbenzyl)-
12 succinamido)-p-xylylene diamide,

13 N,N'-bis(N-(4-aminomethylbenzyl)glutaramido)-N,N'-
14 bis(methyl)-p-xylylene diamide,

15 N,N'-bis(N-(3-aminomethylbenzyl)succinamido)-p-
16 xylylene diamide,

17 N,N'-bis(N-(3-aminomethylbenzyl)succinamido)-m-
18 xylylene diamide,

19 bis(p-xylylenediamineglycine)-1,4-benzene-
20 dimethanol dicarbamate,
21 N-(3-aminomethylbenzylsuccinamido)-N'-(4-aminomethyl-
22 benzylsuccinamido)-p-xylylene diamide,
23 N-(3-aminomethylbenzylsuccinamido)-N'-(4-aminomethyl-
24 benzylsuccinamido)-m-xylylene diamide,
25 bis(p-xylylenediaminesarcosine)-1,4-benzene-
26 dimethanol dicarbamate,
27 bis(1,4-cyclohexyldimethylamine-N-methyl-
28 N-glycine)-1,4-benzenedimethanol dicarbamate,
29 bis(p-xylylenediamine-D-alanine)-1,4-benzene-
30 dimethanol dicarbamate,
31 bis(p-xylylenediamine-L-alanine)-1,4-benzene-
32 dimethanol dicarbamate,
33 N,N'-bis(N-(4-aminomethylbenzyl)butyramido)-
34 terephthalamide,
35 N,N'-bis(N-(4-aminomethylbenzyl)butyramido)-
36 N,N'-bis(methyl)-terephthalamide,
37 N,N'-bis((N-(4-aminomethylbenzyl)succinamido))-p-
38 phenethylene diamide,
39 bis((4-aminomethylanilido)glycine)-1,4-
40 benzenedimethanol dicarbamate,
41 bis((4-guanidomethylanilido)glycine)-1,4-
42 benzenedimethanol dicarbamate,
43 bis((3-aminomethylbenzylamido)glycine)-1,4-
44 benzenedimethanol dicarbamate,
45 bis(N-(4-aminomethylbenzyl)glycyl urea)-p-xylylene
46 diamide,
47 bis(N-(4-aminomethylbenzyl)glycyl urea)-1,4-
48 phenethylene diamide,
49 N,N'-bis(methyl)-bis(glycine-trans-1,4-
50 cyclohexylbis(methylamine)urea)-p-xylylene diamide,
51 N,N'-bis(methyl)-bis(glycine-p-xylylenediamine urea)-
52 p-xylylene diamide,
53 N,N'-bis(methyl)-bis(4-aminomethylbenzoyl-trans-1,4-
54 cyclohexylbis(methylamine)urea)xylylene diamide, and
55 N,N'-bis(methyl)-bis(sarcosine-trans-1,4-
56 cyclohexylbis(methylamine)urea)-p-xylylene diamide.

11. The compound of claim 2, wherein n_1 and n'_1 are both 0 and X^2 is $-C(O)NH-$, and X'^2 is $-NHC(O)-$.

12. The compound of claim 11, wherein X^3 and X'^3 are selected independently from the group consisting of methylene, ethylene, and propylene.

13. The compound of claim 12, wherein Y is 1,3- or 1,4-phenylene or substituted phenylene.

14. The compound of claim 13, which is selected from the group consisting of:

N,N'-bis(4-aminomethylbenzamidopropylene)-1,4-benzenedimethanol dicarbamate,

N,N'-bis(N-(4-aminomethylbenzamido)-4-aminobutyric)-p-xylylene diamide,

N,N'-bis(4-aminomethylbenzamidoethylene)-1,4-benzenedimethanol dicarbamate,

N,N'-bis(4-aminomethylbenzamidobutyl)-terephthalyldiamide.

15. The compound of claim 1, wherein Z is 4-guanidylphenyl.

16. The compound of claim 15, wherein n_1 and n'_1 are both 1, X^1 and X'^1 are both methylene, X^2 is $-C(O)NH-$, and X'^2 is $-NHC(O)-$.

17. The compound of claim 16, wherein X^3 and X'^3 are selected independently from the group consisting of methylene, ethylene, and propylene.

18. The compound of claim 17, wherein Y is 1,3- or 1,4-phenylene or substituted phenylene.

19. The compound of claim 18 is selected from the group consisting of:

N,N'-bis(N-(4-guanidylbenzylamine)malonamido)-p-xylylene diamide,
N,N'-bis(N-(4-guanidylbenzylamino)succinamido)-p-xylylene diamide,
N,N'-bis(N-(4-guanidylbenzylamino)glutaramido)-p-xylylene diamide,
N,N'-bis(4-guanidylbenzylaminecarbonylethylene)-1,4-benzenedimethanol dicarbamate,
N,N'-bis(4-(guanidylbenzylaminecarbonylmethylene)-1,4-benzenedimethanol dicarbamate,
bis((4-guanidylbenzyl)-L-phenylalanineamide-N^α-carbonyl)-1,4-dimethanolbenzene,
bis((4-guanidylbenzyl)-L-prolineamide-N^α-carbonyl)-1,4-dimethanolbenzene,
bis((4-guanidylbenzyl)-L-alanineamide-N^α-carbonyl)-1,4-dimethanolbenzene,
bis((4-guanidylbenzyl)-D-alanineamide-N^α-carbonyl)-1,4-dimethanolbenzene,
bis((R,S)-2-(2-(4-guanidinobenzylamino)-2,3-dehydro-6-piperidone)-1,4-benzenedimethanol dicarbamate [isomer 1],
bis((R,S)-2-(2-(4-guanidinobenzylamino)-2,3-dehydro-6-piperidone)-1,4-benzenedimethanol dicarbamate [isomer 2],
4-(guanidinobenzylamido)glycine-1,4-xylylene diurea,
and
N,N-bis((4-guanidobenzyluriedo)acetyl)]-1,4-xylylene diamide.

20. The compound of claim 1, wherein Z is 4-aminomethylcyclohexyl.

21. The compound of claim 20, wherein n₁ and n'₁ are both 1, X¹ and X'¹ are both methylene, X² is -C(O)NH-, and X'² is -NHC(O)-.

1 22. The compound of claim 21, wher in X^3 and X'^3 are
2 selected independently from the group consisting of methylene,
3 ethylene, and propyl ne.

1 23. The compound of claim 22, wherein Y is 1,3- or
2 1,4-phenylene or substituted phenylene.

1 24. The compound of claim 23 is selected from the
2 group consisting of:

3 N,N'-bis(N-(4-aminomethylcyclohexylmethyl)-
4 glutaramido)-p-xylylene diamide,

5 N,N'-bis(methyl)-bis(N-(4-aminomethylcyclohexyl-
6 methyl)-succinamido)-p-xylylene diamide,

7 N,N'-bis(N-(4-aminomethylcyclohexylmethyl)-
8 succinamido)-p-xylylene diamide,

9 N,N'-bis(methyl)-bis(N-(4-aminomethylcyclohexyl-
10 methyl)-glutaramido)-p-xylylene diamine,

11 bis(1,4-cyclohexyldimethylamineglycine)-1,4-
12 benzenedimethanol dicarbamate, and

13 bis(trans-1,4-cyclohexyldimethylamineglycine)-1,4-
14 benzenedimethanol dicarbamate.

1 25. The compound of claim 20, wherein n_1 and n'_1 are
2 both 0 X^2 is $-C(O)NH-$, and X'^2 is $-NHC(O)-$.

1 26. The compound of claim 25, wherein X^3 and X'^3 are
2 selected independently from the group consisting of methylene,
3 ethylene, and propylene.

1 27. The compound of claim 26, wherein Y is 1,3- or
2 1,4-phenylene or substituted phenylene.

1 28. The compound of claim 27 is selected from the
2 group consisting of:

3 N,N'-bis(trans-4-aminomethylcyclohexyl-1-amido
4 propylene)-1,4-benzenedimethanol dicarbamate,

5 N,N'-bis(trans-4-aminomethylcyclohexyl-1-
6 amidobutyl)-1,4-benzenedimethanol dicarbamate, and

7 bis-[4-N-(4-(aminomethyl)cyclohexylamido)butyroyl)]-
8 1,4-xylylene diamide.

1 29. An aerosol composition for the treatment of
2 immunomediated inflammatory disorders comprising at least one
3 compound of claim 1 in an aerosolized pharmaceutically
4 acceptable carrier or solution or dry powder.

1 30. The composition of claim 29, wherein said
2 compound is a compound of claim 10, claim 14, claim 19,
3 claim 24 or claim 28.

1 31. The composition of claim 29 wherein said
2 inflammatory disorder is asthma.

1 32. The composition of claim 29 wherein said
2 inflammatory disorder is allergic rhinitis.

1 33. The composition of claim 29 wherein said compound
2 is present in a pharmaceutically acceptable carrier solution at
3 a concentration between about 0.1 to 30 mg/ml.

1 34. The composition of claim 29 further comprising a
2 β -adrenergic agonist compound.

1 35. The composition of claim 34 wherein said
2 β -adrenergic agonist compound is selected from the group
3 consisting of albuterol, terbutaline, formoterol, fenoterol,
4 and prenaline.

1 36. The composition of claim 29 further comprising an
2 anti-inflammatory corticosteroid.

1 37. The composition of claim 36 wherein said anti-
2 inflammatory corticosteroid is selected from the group
3 consisting of beclomethasone, triamcinolone, flurisolide, and
4 dexamethasone.

1 38. A pharmaceutical composition comprising at least
2 one compound of claim 1 in combination with a pharmaceutically
3 acceptable carrier.

1 39. The composition of claim 38, wherein said
2 compound is a compound of claim 10, claim 14, claim 19,
3 claim 24 or claim 28.

1 40. The composition of claim 38 wherein the
2 pharmaceutically acceptable carrier comprises a
3 pharmaceutically acceptable topical carrier.

1 41. An aerosol device, comprising the compound of
2 claim 1 in a pharmaceutically acceptable carrier solution or
3 dry powder, and means for converting said solution or dry
4 powder into an aerosol form suitable for inhalation.

1 42. The device of claim 41, wherein said compound is
2 a compound of claim 10, claim 14, claim 19, claim 24 or
3 claim 28.

1 43. The device of claim 41 further comprising a
2 β -adrenergic agonist compound.

1 44. The device of claim 43 wherein said β -adrenergic
2 agonist compound is selected from the group consisting of
3 albuterol, terbutaline, formoterol, fenoterol, and prenaline.

1 45. The device of claim 41 further comprising an
2 anti-inflammatory corticosteroid.

1 46. The device of claim 45 wherein said anti-
2 inflammatory corticosteroid is selected from the group
3 consisting of beclomethasone, triamcinolone, flurisolide, and
4 dexamethasone.

1 47. A device for the treatment of allergic rhinitis,
2 comprising at least one compound of claim 1 in a

3 pharmaceutically acceptable carrier solution or dry powder, and
4 means for converting said solution or dry powder into an
5 aerosol form suitable for intranasal administration.

1 48. The device of claim 47, wherein said compound is
2 a compound of claim 10, claim 14, claim 19, claim 24 or
3 claim 28.

1 49. The device of claim 47 further comprising a
2 β -adrenergic agonist compound.

1 50. The device of claim 49 wherein said β -adrenergic
2 agonist compound is selected from the group consisting of
3 albuterol, terbutaline, formoterol, fenoterol, and prenaline.

1 51. The device of claim 47 further comprising an
2 anti-inflammatory corticosteroid.

1 52. The device of claim 51 wherein said anti-
2 inflammatory corticosteroid is selected from the group
3 consisting of beclomethasone, triamcinolone, flurisolide, and
4 dexamethasone.

1 53. A method for treating an immunomediated
2 inflammatory disorder of the respiratory tract, said method
3 comprising administering to a mammal an inhalant composition
4 comprising at least one compound of claim 1 in an aerosolized
5 pharmaceutically acceptable carrier solution or dry powder.

1 54. The method of claim 53, wherein said compound is
2 a compound of claim 10, claim 14, claim 19, claim 24 or
3 claim 28.

1 55. The method of claim 53 further comprising a
2 β -adrenergic agonist compound.

1 56. The method of claim 55 wherein said β -adrenergic
2 agonist compound is selected from the group consisting of
3 albuterol, terbutaline, formoterol, fenoterol, and prenaline.

1 57. The method of claim 53 further comprising an
2 anti-inflammatory corticosteroid.

1 58. The method of claim 57 wherein said anti-
2 inflammatory corticosteroid is selected from the group
3 consisting of beclomethasone, triamcinolone, flurisolide, and
4 dexamethasone.

1 59. A method for treating immunomediated inflammatory
2 skin conditions, said method comprising administering topically
3 to a mammal a composition comprising a therapeutically
4 effective amount of the compound of claim 1 in a
5 pharmaceutically acceptable topical carrier.

1 60. An aerosol composition for the treatment of
2 immunomediated inflammatory disorders, comprising at least one
3 compound of claim 1, and wherein said composition is
4 aerosolized in a pharmaceutically acceptable carrier solution.

1 61. An oral composition for the treatment of
2 immunomediated inflammatory disorders, comprising at least one
3 compound of claim 1 in a pharmaceutically acceptable carrier
4 solution.

1 62. The composition of claim 61, wherein said
2 compound is N,N'-bis(4-guanidylbenzylaminecarbonylmethylene)-
3 1,4-benzenedimethanol dicarbamate.

1 63. A method of treating rheumatoid arthritis in a
2 mammal, comprising administering to such mammal a
3 therapeutically effective amount of a compound of claim 1 to
4 relieve thereby said rheumatoid arthritis.

1 64. A method of treating conjunctivitis in a mammal,
2 comprising administering to such mammal a therapeutically
3 effective amount of a compound of claim 1 to relieve thereby
4 said conjunctivitis.

1 65. A composition for treating conjunctivitis
2 comprising a therapeutically effective amount of a compound of
3 claim 1 in a pharmaceutically acceptable carrier solution.





Figure 1



* Data obtained from a previous study
that included the same animals

Figure 2




Figure 3




Figure 4




Figure 5.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/06926

A. CLASSIFICATION OF SUBJECT MATTER

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C07C279/18	C07C271/22	C07D207/16	C07C237/34	C07C233/51
	C07C275/24	A61K31/165	A61K31/16	A61K31/27	A61K31/155
	A61K31/17				

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 503 203 (MERRELL DOW PHARMACEUTICALS INC.) 16 September 1992 see claims; examples ---	1-33
A	EP,A,0 214 429 (KOWA CO. LTD.) 18 March 1987 see claims; examples ---	1-33
A	GB,A,1 007 334 (DR. A. WANDER S.A.) 13 October 1965 see claims; examples ---	1-33
A	EP,A,0 580 378 (SHIONOGI & CO. LTD.) 26 January 1994 see whole document ---	1-33
-/--		

X Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A"** document defining the general state of the art which is not considered to be of particular relevance
- "E"** earlier document but published on or after the international filing date
- "L"** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O"** document referring to an oral disclosure, use, exhibition or other means
- "P"** document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

15 September 1995

Date of mailing of the international search report

27. 09. 95

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Helps, I

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/US 95/06926

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	WO,A,94 20527 (ARRIS PHARMACEUTICAL CORPORATION) 15 September 1994 see whole document ----	1-65
P,A	DE,A,43 16 922 (BOEHRINGER MANNHEIM GMBH) 24 November 1994 see whole document -----	1-65

INTERNATIONAL SEARCH REPORT

I: ational application No.

PCT/US 95/06926

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 53-59 and 63-65 are drawn to a method of treatment of the human or animal body by therapy (Rule 39.1.(iv) - PCT), the search has been carried out and based on the alleged effects of the compounds/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr. al Application No
PCT/US 95/06926

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0503203	16-09-92	EP-A- 0504064 JP-A- 5112598 US-A- 5391705	16-09-92 07-05-93 21-02-95
EP-A-0214429	18-03-87	AU-A- 6032886 JP-A- 62103058 US-A- 4746737	29-01-87 13-05-87 24-05-88
GB-A-1007334		DE-A- 1445186 OA-A- 1084 US-A- 3338917 US-A- 3622596	24-10-68 07-08-68 29-08-67 23-11-71
EP-A-0580378	26-01-94	CA-A- 2100640 CN-A- 1088197 HU-A- 64938 JP-A- 6087790	24-01-94 22-06-94 28-03-94 29-03-94
WO-A-9420527	15-09-94	AU-B- 6364794	26-09-94
DE-A-4316922	24-11-94	AU-B- 6927894 WO-A- 9427958	20-12-94 08-12-94